BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771. [PMID: 22236411 DOI: 10.1136/bmj.d7771] [Cited by in Crossref: 570] [Cited by in F6Publishing: 601] [Article Influence: 57.0] [Reference Citation Analysis]
Number Citing Articles
1 Nehme R, Diab-assaf M, Decombat C, Delort L, Caldefie-chezet F. Targeting Adiponectin in Breast Cancer. Biomedicines 2022;10:2958. [DOI: 10.3390/biomedicines10112958] [Reference Citation Analysis]
2 Przybysz JT, Dibrog AM, Kern KA, Mukherjee A, Japa JE, Waite MH, Mietlicki-baase EG. Macronutrient intake: Hormonal controls, pathological states, and methodological considerations. Appetite 2022. [DOI: 10.1016/j.appet.2022.106365] [Reference Citation Analysis]
3 Ghusn W, Hurtado MD, Acosta A. Weight-centric treatment of type 2 diabetes mellitus brief running title: Clinical review of weight-centric diabetes treatments. Obesity Pillars 2022. [DOI: 10.1016/j.obpill.2022.100045] [Reference Citation Analysis]
4 Franch-nadal J, Granado-casas M, Mata-cases M, Ortega E, Vlacho B, Mauricio D. Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world. Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.10.005] [Reference Citation Analysis]
5 Zaki AM, Abo-elnour DE, Abdalla YE, Hassan RY, Salama MK, Elboraay T, Abdelhaleem IA. Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2022;16:102657. [DOI: 10.1016/j.dsx.2022.102657] [Reference Citation Analysis]
6 Carydias E, Tasho A, Kani C, Bacopoulou F, Stefanaki C, Markantonis SL. Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2. Children (Basel) 2022;9:1572. [PMID: 36291508 DOI: 10.3390/children9101572] [Reference Citation Analysis]
7 El Meouchy P, Wahoud M, Allam S, Chedid R, Karam W, Karam S. Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. Int J Mol Sci 2022;23:12305. [PMID: 36293177 DOI: 10.3390/ijms232012305] [Reference Citation Analysis]
8 Miao H, Zou C, Yang S, Chia YC, Van Huynh M, Sogunuru GP, Tay JC, Wang TD, Kario K, Zhang Y. Targets and management of hypertension in heart failure: focusing on the stages of heart failure. J Clin Hypertens (Greenwich) 2022;24:1218-25. [PMID: 36196463 DOI: 10.1111/jch.14553] [Reference Citation Analysis]
9 Amusin DB, Kuchta K, Ewing T, Tucker L, Campbell M, Ujiki MB, Billings LK. Association between hemoglobin A1C response to glucagon-like peptide-1 receptor agonists and hemoglobin A1C and weight outcomes post-bariatric surgery. Obesity Medicine 2022;35:100450. [DOI: 10.1016/j.obmed.2022.100450] [Reference Citation Analysis]
10 Vosoughi K, Salman Roghani R, Camilleri M. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. Obesity Medicine 2022;35:100456. [DOI: 10.1016/j.obmed.2022.100456] [Reference Citation Analysis]
11 Durell N, Franks R, Coon S, Cowart K, Carris NW. Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss. Journal of Pharmacy Technology 2022;38:283-288. [DOI: 10.1177/87551225221110850] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Alicic RZ, Neumiller JJ, Galindo RJ, Tuttle KR. Use of Glucose-Lowering Agents in Diabetes and Chronic Kidney Disease. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.09.018] [Reference Citation Analysis]
13 Wu Q, Li D, Huang C, Zhang G, Wang Z, Liu J, Yu H, Song B, Zhang N, Li B, Chu X. Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. Biomedicine & Pharmacotherapy 2022;153:113517. [DOI: 10.1016/j.biopha.2022.113517] [Reference Citation Analysis]
14 Wu W, Zhou Q, Yuan P, Qiao D, Deng S, Cheng H, Ren Y. A Novel Multiphase Modified Ketogenic Diet: An Effective and Safe Tool for Weight Loss in Chinese Obese Patients. Diabetes Metab Syndr Obes 2022;15:2521-34. [PMID: 35999869 DOI: 10.2147/DMSO.S365192] [Reference Citation Analysis]
15 Karamanakos G, Kokkinos A, Dalamaga M, Liatis S. Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications. Curr Obes Rep 2022. [PMID: 35931912 DOI: 10.1007/s13679-022-00477-x] [Reference Citation Analysis]
16 Hernández C, Gómez-Peralta F, Simó-Servat O, García-Ramírez M, Abreu C, Gómez-Rodríguez S, Simó R. Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists. Acta Diabetol 2022. [PMID: 35925404 DOI: 10.1007/s00592-022-01928-6] [Reference Citation Analysis]
17 van Ruiten CC, Veltman DJ, Wijdeveld M, Ten Kulve JS, Kramer MHH, Nieuwdorp M, IJzerman RG. Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab 2022;24:1588-97. [PMID: 35491524 DOI: 10.1111/dom.14732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang L, Yu WJ, Zhu H, Li HF, Qiao J. Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report. World J Clin Cases 2022; 10(21): 7495-7501 [DOI: 10.12998/wjcc.v10.i21.7495] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Janez A, Muzurovic E, Stoian AP, Haluzik M, Guja C, Czupryniak L, Duvnjak L, Lalic N, Tankova T, Bogdanski P, Papanas N, Nunes JS, Kempler P, Fras Z, Rizzo M. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol 2022:S0167-5273(22)01085-3. [PMID: 35905827 DOI: 10.1016/j.ijcard.2022.07.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Ölmestig J, Marlet IR, Vilsbøll T, Rungby J, Rostrup E, Lambertsen KL, Kruuse C. A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 2022;14:899389. [DOI: 10.3389/fnagi.2022.899389] [Reference Citation Analysis]
21 Ito K, Satoh S, Kondo Y, Tamura H, Hasebe M, Terauchi Y. Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study. Diabetol Int. [DOI: 10.1007/s13340-022-00592-z] [Reference Citation Analysis]
22 Neumiller JJ, Alicic RZ, Tuttle KR. GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease. Kidney and Dialysis 2022;2:386-398. [DOI: 10.3390/kidneydial2030034] [Reference Citation Analysis]
23 Meyer J, Dreischmeier E, Lehmann M, Phelan J. The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes. Ann Pharmacother 2022;:10600280221107381. [PMID: 35778801 DOI: 10.1177/10600280221107381] [Reference Citation Analysis]
24 Volpe S, Lisco G, Racaniello D, Fanelli M, Colaianni V, Vozza A, Triggiani V, Sabbà C, Tortorella C, De Pergola G, Piazzolla G. Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study. Nutrients 2022;14:2414. [PMID: 35745144 DOI: 10.3390/nu14122414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Aberle J, Lautenbach A, Meyhöfer S, Meyhöfer SM, Selig L, Blüher M, Menzen M. Adipositas und Diabetes. Diabetologie 2022;18:418-425. [DOI: 10.1007/s11428-022-00903-7] [Reference Citation Analysis]
26 Ranjit R, Alexandrovna Lapik I, Minkailovna Gapparova K, Vladimirovich Galchenko A. Bariatric Surgery. Nutr Today 2022;57:117-144. [DOI: 10.1097/nt.0000000000000540] [Reference Citation Analysis]
27 Ding C, Tang Y, Zhu W, Huang P, Lian P, Ran J, Huang X. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. Acta Diabetol 2022;59:519-33. [PMID: 34988690 DOI: 10.1007/s00592-021-01830-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Dhore-Patil A, Thannoun T, Samson R, Le Jemtel TH. Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity. Front Physiol 2021;12:785879. [PMID: 35242044 DOI: 10.3389/fphys.2021.785879] [Reference Citation Analysis]
29 Wretlind A, Zobel EH, de Zawadzki A, Ripa RS, Curovic VR, von Scholten BJ, Mattila IM, Hansen TW, Kjær A, Vestergaard H, Rossing P, Legido-quigley C. Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Front Clin Diabetes Healthc 2022;3. [DOI: 10.3389/fcdhc.2022.856485] [Reference Citation Analysis]
30 Luo J, Gabriel N, Korytkowski M, Hernandez I, Gellad WF. Association of Formulary Restrictions and Initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109855] [Reference Citation Analysis]
31 Kuchay MS, Misra A. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. Diabetes Metab Syndr 2022;16:102446. [PMID: 35259705 DOI: 10.1016/j.dsx.2022.102446] [Reference Citation Analysis]
32 Mehan S, Bhalla S, Siddiqui EM, Sharma N, Shandilya A, Khan A. Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration. DNND 2022;Volume 12:31-59. [DOI: 10.2147/dnnd.s247153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Górriz JL, Romera I, Cobo A, O'Brien PD, Merino-Torres JF. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. Diabetes Ther 2022;13:389-421. [PMID: 35175551 DOI: 10.1007/s13300-021-01198-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, Zhou HD. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev 2022;:e13435. [PMID: 35194917 DOI: 10.1111/obr.13435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
35 Maevskaya M, Kotovskaya Y, Ivashkin V, Tkacheva O, Troshina E, Shestakova M, Breder V, Geyvandova N, Doschitsin V, Dudinskaya E, Ershova E, Kodzoeva K, Komshilova K, Korochanskaya N, Mayorov A, Mishina E, Nadinskaya M, Nikitin I, Pogosova N, Tarzimanova A, Shamkhalova M. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. [DOI: 10.26442/00403660.2022.02.201363] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Wu T, Wong CK, Tang EH, Man KK, Wong SK, Ho Au IC, Tse ET, Chan EW, Grieve E, Wu O, Ng EK, Wong IC. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: A retrospective cohort study. Surgery for Obesity and Related Diseases 2022. [DOI: 10.1016/j.soard.2022.02.008] [Reference Citation Analysis]
37 Pratley RE, Jacob S, Baek S, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Shaunik A, Yoon KH. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Res Care 2022;10:e002207. [PMID: 35042751 DOI: 10.1136/bmjdrc-2021-002207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 van Ruiten CC, Ten Kulve JS, van Bloemendaal L, Nieuwdorp M, Veltman DJ, IJzerman RG. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology 2022;137:105667. [PMID: 35033928 DOI: 10.1016/j.psyneuen.2022.105667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Fadah K, Alashi A, Deoker A. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. Curr Cardiol Rep 2022. [PMID: 35000149 DOI: 10.1007/s11886-021-01619-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Bandeira F, Moura F, Costi BB, Cardoso ACSM. GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes. Endocrinology and Diabetes 2022. [DOI: 10.1007/978-3-030-90684-9_31] [Reference Citation Analysis]
41 Velikova TV, Nakov RV, Ianiro G. Medication and Health Risks Associated With Neglected Side Effects on Gut Microbiota. Comprehensive Gut Microbiota 2022. [DOI: 10.1016/b978-0-12-819265-8.00074-7] [Reference Citation Analysis]
42 Stewart E, Selzer A. Preoperative optimization of diabetes. Int Anesthesiol Clin 2022;60:8-15. [PMID: 34897217 DOI: 10.1097/AIA.0000000000000351] [Reference Citation Analysis]
43 Guo Z, Wu Y, Zhu L, Wang Y, Wang D, Sun X. PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration. BMC Endocr Disord 2021;21:245. [PMID: 34923973 DOI: 10.1186/s12902-021-00908-1] [Reference Citation Analysis]
44 Safar MM, Abdelkader NF, Ramadan E, Kortam MA, Mohamed AF. Novel mechanistic insights towards the repositioning of alogliptin in Parkinson's disease. Life Sci 2021;287:120132. [PMID: 34774622 DOI: 10.1016/j.lfs.2021.120132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
45 Gao L, Huang H, Zhang L, Zhang N, Fu Y, Zhu D, Bi Y, Feng W. Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. Exp Clin Endocrinol Diabetes 2021. [PMID: 34856624 DOI: 10.1055/a-1608-0345] [Reference Citation Analysis]
46 Uto A, Miyashita K, Endo S, Sato M, Ryuzaki M, Kinouchi K, Mitsuishi M, Meguro S, Itoh H. Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice With Histone Acetylation in Dpp-4 Promoter. Endocrinology 2021;162:bqab193. [PMID: 34480538 DOI: 10.1210/endocr/bqab193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Aberle J, Lautenbach A, Meyhöfer S, Meyhöfer SM, Selig L, Blüher M, Menzen M. Adipositas und Diabetes. Diabetologie und Stoffwechsel 2021;16:S290-8. [DOI: 10.1055/a-1515-8779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
48 Tanabe H, Masuzaki H, Shimabukuro M. Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective. Diabetes Res Clin Pract 2021;180:109067. [PMID: 34563587 DOI: 10.1016/j.diabres.2021.109067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
49 Huang YZ, Yang GY, Wang C, Chen XY, Zhang LL. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. World J Diabetes 2021; 12(9): 1576-1586 [PMID: 34630909 DOI: 10.4239/wjd.v12.i9.1576] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Alexander JT, Staab EM, Wan W, Franco M, Knitter A, Skandari MR, Bolen S, Maruthur NM, Huang ES, Philipson LH, Winn AN, Thomas CC, Zeytinoglu M, Press VG, Tung EL, Gunter K, Bindon B, Jumani S, Laiteerapong N. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med 2021. [PMID: 34508290 DOI: 10.1007/s11606-021-07105-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
51 Ma R, Zou Y, Wang W, Zheng Q, Feng Y, Dong H, Tan Z, Zeng X, Zhao Y, Deng Y, Wang Y, Sun A. Obesity management in polycystic ovary syndrome: disparity in knowledge between obstetrician-gynecologists and reproductive endocrinologists in China. BMC Endocr Disord 2021;21:182. [PMID: 34488736 DOI: 10.1186/s12902-021-00848-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
52 Jin ZL, Liu W. Progress in treatment of type 2 diabetes by bariatric surgery. World J Diabetes 2021; 12(8): 1187-1199 [PMID: 34512886 DOI: 10.4239/wjd.v12.i8.1187] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
53 Twells LK, Harris Walsh K, Blackmore A, Adey T, Donnan J, Peddle J, Ryan D, Farrell A, Nguyen H, Gao Z, Pace D. Nonsurgical weight loss interventions: A systematic review of systematic reviews and meta-analyses. Obes Rev 2021;:e13320. [PMID: 34378849 DOI: 10.1111/obr.13320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Bethea M, Bozadjieva-Kramer N, Sandoval DA. Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion. Endocrinology 2021;162:bqab150. [PMID: 34318874 DOI: 10.1210/endocr/bqab150] [Reference Citation Analysis]
55 Kalsbeek MJT, Yi CX. The infundibular peptidergic neurons and glia cells in overeating, obesity, and diabetes. Handb Clin Neurol 2021;180:315-25. [PMID: 34225937 DOI: 10.1016/B978-0-12-820107-7.00019-7] [Reference Citation Analysis]
56 Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D'Addio F, Zuccotti GV, Fiorina P. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res 2021;171:105782. [PMID: 34302978 DOI: 10.1016/j.phrs.2021.105782] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
57 Li Q, Jia M, Yan Z, Li Q, Sun F, He C, Li Y, Zhou X, Zhang H, Liu X, Bu X, Gao P, He H, Zhao Z, Zhu Z. Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway. J Am Heart Assoc 2021;10:e020734. [PMID: 34250817 DOI: 10.1161/JAHA.120.020734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
58 Wang L, Xin Q, Wang Y, Chen Z, Yuan R, Miao Y, Zhang G, Cong W. Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2021;171:105765. [PMID: 34252552 DOI: 10.1016/j.phrs.2021.105765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Quast DR, Nauck MA, Schenker N, Menge BA, Kapitza C, Meier JJ. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes Obes Metab 2021;23:2344-53. [PMID: 34189834 DOI: 10.1111/dom.14477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ertuglu LA, Porrini E, Hornum M, Demiray A, Afsar B, Ortiz A, Covic A, Rossing P, Kanbay M. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. Transpl Int 2021;34:1341-59. [PMID: 33880815 DOI: 10.1111/tri.13883] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
61 Brierley DI, de Lartigue G. Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br J Pharmacol 2021. [PMID: 34185884 DOI: 10.1111/bph.15603] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
62 Salim OA. A letter to the editor: the effects of high intensity interval training on appetite management in individuals with type 2 diabetes: influenced by participant's weight. J Diabetes Metab Disord 2021;20:1065-6. [PMID: 34178872 DOI: 10.1007/s40200-021-00818-y] [Reference Citation Analysis]
63 Ma R, Ding X, Wang Y, Deng Y, Sun A. The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e26295. [PMID: 34115034 DOI: 10.1097/MD.0000000000026295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
64 Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. J Clin Pharm Ther 2020;45 Suppl 1:17-27. [PMID: 32910490 DOI: 10.1111/jcpt.13230] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 24.0] [Reference Citation Analysis]
65 Gourgari E, Huerta-Saenz L, Tonyushkina KN, Rosolowsky ET, Guttmann-Bauman I. Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives. Pediatr Diabetes 2021;22:872-5. [PMID: 34018306 DOI: 10.1111/pedi.13234] [Reference Citation Analysis]
66 Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, dapagliflozin or phentermine/topiramate differentially affect metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab 2021:dgab408. [PMID: 34097062 DOI: 10.1210/clinem/dgab408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
67 Simental-Mendía LE, Sánchez-García A, Linden-Torres E, Simental-Mendía M. Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2021;177:108899. [PMID: 34098057 DOI: 10.1016/j.diabres.2021.108899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Pathak MP, Patowary P, Goyary D, Das A, Chattopadhyay P. β-caryophyllene ameliorated obesity-associated airway hyperresponsiveness through some non-conventional targets. Phytomedicine 2021;89:153610. [PMID: 34175589 DOI: 10.1016/j.phymed.2021.153610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Tanaka A, Node K. Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. Hypertens Res 2021;44:897-905. [PMID: 33990790 DOI: 10.1038/s41440-021-00665-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
70 Zhang Y, Rahematpura S, Ragnini KH, Moreno A, Stecyk KS, Kahng MW, Milliken BT, Hayes MR, Doyle RP, Schmidt HD. A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats. Neuropharmacology 2021;192:108599. [PMID: 33965397 DOI: 10.1016/j.neuropharm.2021.108599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
71 Pérez-Belmonte LM, Ricci M, Sanz-Cánovas J, Cobos-Palacios L, López-Carmona MD, Ruiz-Moreno MI, Millán-Gómez M, Bernal-López MR, Jansen-Chaparro S, Gómez-Huelgas R. De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study. J Clin Med 2021;10:2013. [PMID: 34066707 DOI: 10.3390/jcm10092013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Khunti K, Charbonnel B, Cooper A, Gomes MB, Ji L, Leigh P, Nicolucci A, Rathmann W, Shestakova MV, Siddiqui A, Tang F, Watada H, Chen H; DISCOVER investigators. Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study. Diabetes Obes Metab 2021;23:1823-33. [PMID: 33852202 DOI: 10.1111/dom.14400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
73 Pirlet C, Poirier P, Cieza T, Piché ME, Biertho L, Maes F, Ruzsa Z, Bertrand OF. Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease. Am J Cardiovasc Drugs 2021;21:271-81. [PMID: 32812206 DOI: 10.1007/s40256-020-00428-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
74 Camastra S, Palumbo M, Santini F. Nutrients handling after bariatric surgery, the role of gastrointestinal adaptation. Eat Weight Disord 2021. [PMID: 33895917 DOI: 10.1007/s40519-021-01194-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
75 Hunt JE, Holst JJ, Jeppesen PB, Kissow H. GLP-1 and Intestinal Diseases. Biomedicines 2021;9:383. [PMID: 33916501 DOI: 10.3390/biomedicines9040383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
76 Jones S, Luo S, Dorton HM, Yunker AG, Angelo B, Defendis A, Monterosso JR, Page KA. Obesity and Dietary Added Sugar Interact to Affect Postprandial GLP-1 and Its Relationship to Striatal Responses to Food Cues and Feeding Behavior. Front Endocrinol (Lausanne) 2021;12:638504. [PMID: 33868172 DOI: 10.3389/fendo.2021.638504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
77 Ma K, Tang D, Yu C, Zhao L. Progress in research on the roles of TGR5 receptor in liver diseases. Scand J Gastroenterol 2021;56:717-26. [PMID: 33771073 DOI: 10.1080/00365521.2021.1903547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
78 Wegeberg AM, Meldgaard T, Baek A, Drewes AM, Vyberg M, Jessen N, Brock B, Brock C. Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes. Basic Clin Pharmacol Toxicol 2021;128:773-82. [PMID: 33624417 DOI: 10.1111/bcpt.13575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Köseoğlu D, Koparal SS, Özdemir Başer Ö, Berker D. Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study. Turk J Med Sci 2021;51:167-74. [PMID: 32892547 DOI: 10.3906/sag-2004-154] [Reference Citation Analysis]
80 Alanteet AA, Attia HA, Shaheen S, Alfayez M, Alshanawani B. Anti-Proliferative Activity of Glucagon-Like Peptide-1 Receptor Agonist on Obesity-Associated Breast Cancer: The Impact on Modulating Adipokines' Expression in Adipocytes and Cancer Cells. Dose Response 2021;19:1559325821995651. [PMID: 33746653 DOI: 10.1177/1559325821995651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
81 Dedov II, Shestakova MV, Melnichenko GA, Mazurina NV, Andreeva EN, Bondarenko IZ, Gusova ZR, Dzgoeva FK, Eliseev MS, Ershova EV, Zhuravleva MV, Zakharchuk TA, Isakov VA, Klepikova MV, Komshilova KA, Krysanova VS, Nedogoda SV, Novikova AM, Ostroumova OD, Pereverzev AP, Rozhivanov RV, Romantsova TI, Ruyatkina LA, Salasyuk AS, Sasunova AN, Smetanina SA, Starodubova AV, Suplotova LA, Tkacheva ON, Troshina EA, Khamoshina MV, Chechelnitskaya SM, Shestakova EA, Sheremet’eva EV. INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obes metabol 2021;18:5-99. [DOI: 10.14341/omet12714] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
82 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
83 Millman JF, Okamoto S, Teruya T, Uema T, Ikematsu S, Shimabukuro M, Masuzaki H. Extra-virgin olive oil and the gut-brain axis: influence on gut microbiota, mucosal immunity, and cardiometabolic and cognitive health. Nutr Rev 2021:nuaa148. [PMID: 33576418 DOI: 10.1093/nutrit/nuaa148] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
84 Farmer RE, Beard I, Raza SI, Gollop ND, Patel N, Tebboth A, McGovern AP, Kanumilli N, Ternouth A. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD. Clin Ther 2021;43:320-35. [PMID: 33581878 DOI: 10.1016/j.clinthera.2020.12.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
85 Michałowska J, Miller-Kasprzak E, Bogdański P. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients 2021;13:351. [PMID: 33503878 DOI: 10.3390/nu13020351] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
86 Bertoccini L, Baroni MG. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. Adv Exp Med Biol 2021;1307:193-212. [PMID: 32034729 DOI: 10.1007/5584_2020_494] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 15.0] [Reference Citation Analysis]
87 Tsilingiris D, Liatis S, Dalamaga M, Kokkinos A. The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications. Curr Obes Rep 2020;9:136-49. [PMID: 32388792 DOI: 10.1007/s13679-020-00378-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
88 Hamedi Z, Mishriky BM, Okunrintemi V, Powell JR, Cummings DM. GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials. Diabetes Metab Res Rev 2021;37:e3436. [PMID: 33440044 DOI: 10.1002/dmrr.3436] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
89 Draper M, Willems M, Malahe RK, Hamilton A, Tarasov AI. Imaging Meets Cytometry: Analyzing Heterogeneous Functional Microscopic Data from Living Cell Populations. J Imaging 2021;7:9. [PMID: 34460580 DOI: 10.3390/jimaging7010009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Sapio MR, Vazquez FA, Loydpierson AJ, Maric D, Kim JJ, LaPaglia DM, Puhl HL, Lu VB, Ikeda SR, Mannes AJ, Iadarola MJ. Comparative Analysis of Dorsal Root, Nodose and Sympathetic Ganglia for the Development of New Analgesics. Front Neurosci 2020;14:615362. [PMID: 33424545 DOI: 10.3389/fnins.2020.615362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
91 Clément K, Ziegler O. Pharmacologie de l'obésité : vers de nouvelles options. Les Obésités 2021. [DOI: 10.1016/b978-2-294-76753-1.00116-8] [Reference Citation Analysis]
92 Veelen A, Erazo-Tapia E, Oscarsson J, Schrauwen P. Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment? Mol Metab 2021;46:101158. [PMID: 33387681 DOI: 10.1016/j.molmet.2020.101158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
93 Chadda KR, Cheng TS, Ong KK. GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis. Obes Rev. 2021;22:e13177. [PMID: 33354917 DOI: 10.1111/obr.13177] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
94 Nowrouzi-Sohrabi P, Rezaei S, Jalali M, Ashourpour M, Ahmadipour A, Keshavarz P, Akbari H. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol 2021;893:173823. [PMID: 33352183 DOI: 10.1016/j.ejphar.2020.173823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Ryan MJ. Have a heart: failure to increase GLP-1 caused by heart failure increases the risk of diabetes. Clin Sci (Lond) 2020;134:3119-21. [PMID: 33269792 DOI: 10.1042/CS20201029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Elbasan O, Sisman P, Peynirci H, Yabaci A, Ersoy C. Comparison Between Sleeve Gastrectomy and Exenatide on Type 2 Diabetic Patients. Bariatric Surgical Practice and Patient Care 2020;15:199-204. [DOI: 10.1089/bari.2019.0041] [Reference Citation Analysis]
97 Ding QY, Tian JX, Li M, Lian FM, Zhao LH, Wei XX, Han L, Zheng YJ, Gao ZZ, Yang HY, Fang XY, Tong XL. Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota. Front Cell Infect Microbiol 2020;10:530160. [PMID: 33194785 DOI: 10.3389/fcimb.2020.530160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
98 Л. А. Жабіцька. Polycystic ovary syndrome: individualized approach to treatment. Literature review. RE 2020. [DOI: 10.18370/2309-4117.2020.54.89-94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Chang KC, Shao SC, Kuo S, Yang CY, Chen HY, Chan YY, Ou HT. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis. Cardiovasc Diabetol 2020;19:172. [PMID: 33036617 DOI: 10.1186/s12933-020-01148-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
100 Tandon S, Ayis S, Hopkins D, Harding S, Stadler M. The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2021;23:350-62. [PMID: 33026152 DOI: 10.1111/dom.14221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
101 Makri E, Kita M, Goulas A, Papaioannidou P, Efstathiadou ZA, Adamidou F, Polyzos SA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes Metab Syndr 2020;14:1913-9. [PMID: 33011499 DOI: 10.1016/j.dsx.2020.09.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
102 Honigberg MC, Chang LS, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. JAMA Cardiol 2020;5:1182-90. [PMID: 32584928 DOI: 10.1001/jamacardio.2020.1966] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 16.5] [Reference Citation Analysis]
103 Kaneto H, Koshida R, Baxter M. Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge. Diabetes Obes Metab 2020;22:24-34. [DOI: 10.1111/dom.14095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
104 Martins EB, Lima EG, Pitta FG, Carvalho LNS, Queiroz TDD, Serrano Júnior CV. Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes. Rev Assoc Med Bras 2020;66:1283-1288. [DOI: 10.1590/1806-9282.66.9.1283] [Reference Citation Analysis]
105 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
106 Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, Emsley HC. GLP-1 receptor agonists for Parkinson's disease. Cochrane Database Syst Rev 2020;7:CD012990. [PMID: 32700772 DOI: 10.1002/14651858.CD012990.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
107 Sievers W, Rathner JA, Green RA, Kettle C, Irving HR, Whelan DR, Fernandez RGD, Zacharias A. Innervation of supraclavicular adipose tissue: A human cadaveric study. PLoS One 2020;15:e0236286. [PMID: 32702004 DOI: 10.1371/journal.pone.0236286] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Carmena R, Ascaso JF, Redon J. Chronic kidney disease as a cardiovascular risk factor. J Hypertens 2020;38:2110-21. [PMID: 32649622 DOI: 10.1097/HJH.0000000000002506] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
109 Heinitz S. Behandlung adipöser Jugendlicher mit Liraglutid. Diabetologe 2020;16:528-529. [DOI: 10.1007/s11428-020-00632-9] [Reference Citation Analysis]
110 Tičinović Kurir T, Miličević T, Novak A, Vilović M, Božić J. ADROPIN - POTENTIAL LINK IN CARDIOVASCULAR PROTECTION FOR OBESE MALE TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH LIRAGLUTIDE. Acta Clin Croat 2020;59:344-50. [PMID: 33456123 DOI: 10.20471/acc.2020.59.02.19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
111 Ruban A, Stoenchev K, Ashrafian H, Teare J. Current treatments for obesity. Clin Med (Lond) 2019;19:205-12. [PMID: 31092512 DOI: 10.7861/clinmedicine.19-3-205] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 20.0] [Reference Citation Analysis]
112 Juel CTB, Lund A, Andersen MM, Hansen CP, Storkholm JH, Rehfeld JF, van Hall G, Hartmann B, Wewer Albrechtsen NJ, Holst JJ, Vilsbøll T, Knop FK. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. Diabetologia 2020;63:1285-98. [DOI: 10.1007/s00125-020-05158-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
113 Dagbasi A, Lett AM, Murphy K, Frost G. Understanding the interplay between food structure, intestinal bacterial fermentation and appetite control. Proc Nutr Soc 2020;:1-17. [PMID: 32383415 DOI: 10.1017/S0029665120006941] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
114 Vally M. Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management. SAGP 2020. [DOI: 10.36303/sagp.2020.1.1.0006] [Reference Citation Analysis]
115 Bays HE, Kozlovski P, Shao Q, Proot P, Keefe D. Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Obesity (Silver Spring). 2020;28:870-881. [PMID: 32187881 DOI: 10.1002/oby.22764] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
116 Davis EM, Sandoval DA. Glucagon‐Like Peptide‐1: Actions and Influence on Pancreatic Hormone Function. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 577-95. [DOI: 10.1002/cphy.c190025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
117 Yokote K, Sano M, Tsumiyama I, Keefe D. Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. Diabetes Obes Metab. 2020;22:1102-1110. [PMID: 32072763 DOI: 10.1111/dom.14006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
118 Weghuber D, Forslund A, Ahlström H, Alderborn A, Bergström K, Brunner S, Cadamuro J, Ciba I, Dahlbom M, Heu V, Hofmann J, Kristinsson H, Kullberg J, Ladinger A, Lagler FB, Lidström M, Manell H, Meirik M, Mörwald K, Roomp K, Schneider R, Vilén H, Widhalm K, Zsoldos F, Bergsten P. A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity. Pediatric Obesity 2020;15. [DOI: 10.1111/ijpo.12624] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
119 Nauck MA. The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism 2020;103:154031. [DOI: 10.1016/j.metabol.2019.154031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
120 Davidson JA, Stager W, Paranjape S, Berria R, Leiter LA. Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. Clin Diabetes Endocrinol 2020;6:2. [PMID: 31956422 DOI: 10.1186/s40842-019-0088-5] [Reference Citation Analysis]
121 Khalil H, Ellwood L, Lord H, Fernandez R. Pharmacological Treatment for Obesity in Adults: An Umbrella Review. Ann Pharmacother 2020;54:691-705. [PMID: 31958967 DOI: 10.1177/1060028019898912] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
122 Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Inflammatory Mechanisms in Diabetic Kidney Disease. Obesity and Diabetes 2020. [DOI: 10.1007/978-3-030-53370-0_32] [Reference Citation Analysis]
123 Gastaldelli A. NAFLD and Insulin Resistance: A Multisystemic Disease. Non-Alcoholic Fatty Liver Disease 2020. [DOI: 10.1007/978-3-319-95828-6_4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Potential cardiovascular benefits of GLP-1 analogues : evidence and implications for type 2 diabetes management. South African General Practitioner 2020;1:24-29. [DOI: 10.36303/sagp.2020.1.0006] [Reference Citation Analysis]
125 Sandow J. Pharmacodynamic Evaluation: Diabetic Methodologies. Drug Discovery and Evaluation: Methods in Clinical Pharmacology 2020. [DOI: 10.1007/978-3-319-56637-5_33-1] [Reference Citation Analysis]
126 Cox EJ, Alicic RZ, Neumiller JJ, Tuttle KR, Providence Medical Research Center, Providence Health and Services, Spokane, WA, USA, Providence Medical Research Center, Providence Health and Services, Spokane, WA, USA, University of Washington School of Medicine, University of Washington, Spokane and Seattle, WA, USA, Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA, Providence Medical Research Center, Providence Health and Services, Spokane, WA, USA, Nephrology Division, Kidney Research Institute, and Institute of Translational Health Sciences, University of Washington, Spokane and Seattle, WA, USA. Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists. US Endocrinology 2020;16:80. [DOI: 10.17925/use.2020.16.2.80] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
127 Sandow J. Pharmacodynamic Evaluation: Diabetic Methodologies. Drug Discovery and Evaluation: Methods in Clinical Pharmacology 2020. [DOI: 10.1007/978-3-319-68864-0_33] [Reference Citation Analysis]
128 Torres Fernandez ED, Huffman AM, Syed M, Romero DG, Yanes Cardozo LL. Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS. Endocrinology 2019;160:2787-99. [PMID: 31593246 DOI: 10.1210/en.2019-00450] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
129 Rebello CJ, Greenway FL. Obesity medications in development. Expert Opin Investig Drugs 2020;29:63-71. [PMID: 31847611 DOI: 10.1080/13543784.2020.1705277] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
130 Nassif ME, Kosiborod M. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. Am J Cardiol 2019;124 Suppl 1:S12-9. [PMID: 31741435 DOI: 10.1016/j.amjcard.2019.10.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
131 Kotsis V, Jordan J, Stabouli S, Antza C, Micic D, Jelaković B, Schlaich MP, Nilsson PM, Kreutz R, Mancia G, Tsioufis K, Grassi G. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. J Hypertens 2020;38:377-86. [PMID: 31764586 DOI: 10.1097/HJH.0000000000002279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
132 Bae JH, Choi HJ, Cho KIK, Kim LK, Kwon JS, Cho YM. Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus. Diabetes Metab J 2020;44:248-59. [PMID: 31701698 DOI: 10.4093/dmj.2019.0018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
133 Fiorentino TV, Casiraghi F, Davalli AM, Finzi G, La Rosa S, Higgins PB, Abrahamian GA, Marando A, Sessa F, Perego C, Guardado-Mendoza R, Kamath S, Ricotti A, Fiorina P, Daniele G, Paez AM, Andreozzi F, Bastarrachea RA, Comuzzie AG, Gastaldelli A, Chavez AO, Di Cairano ES, Frost P, Luzi L, Dick EJ, Halff GA, DeFronzo RA, Folli F. Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas. JCI Insight 2019;4:93091. [PMID: 31536476 DOI: 10.1172/jci.insight.93091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
134 Kaya D, Kaji K, Tsuji Y, Yamashita S, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. Cells 2019;8:E1153. [PMID: 31561561 DOI: 10.3390/cells8101153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
135 Zhang JM, Sun YS, Zhao LQ, Chen TT, Fan MN, Jiao HC, Zhao JP, Wang XJ, Li FC, Li HF, Lin H. SCFAs-Induced GLP-1 Secretion Links the Regulation of Gut Microbiome on Hepatic Lipogenesis in Chickens. Front Microbiol 2019;10:2176. [PMID: 31616396 DOI: 10.3389/fmicb.2019.02176] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
136 Franch-Nadal J, Mata-Cases M, Ortega E, Real J, Gratacòs M, Vlacho B, Vallés JA, Mauricio D. Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. J Clin Med 2019;8:E1389. [PMID: 31491916 DOI: 10.3390/jcm8091389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
137 Thangaraju P, Venkatesan S. Monotherapy with liraglutide - Points to be focussed. J Family Med Prim Care 2019;8:2551-2. [PMID: 31463296 DOI: 10.4103/jfmpc.jfmpc_435_19] [Reference Citation Analysis]
138 Pratley RE, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Jacob S, Yoon KH. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes Obes Metab 2019;21:2429-39. [PMID: 31264757 DOI: 10.1111/dom.13824] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
139 Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-20. [PMID: 31399438 DOI: 10.2337/dc19-0415] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
140 Chia CW, Egan JM. Incretins in obesity and diabetes. Ann N Y Acad Sci. 2020;1461:104-126. [PMID: 31392745 DOI: 10.1111/nyas.14211] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
141 Kalra S, Das AK, Sahay RK, Baruah MP, Tiwaskar M, Das S, Chatterjee S, Saboo B, Bantwal G, Bhattacharya S, Priya G, Chawla M, Brar K, Raza SA, Aamir AH, Shrestha D, Somasundaram N, Katulanda P, Afsana F, Selim S, Naseri MW, Latheef A, Sumanatilleke M. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Ther 2019;10:1645-717. [PMID: 31359367 DOI: 10.1007/s13300-019-0669-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
142 Harger A, Stemmer K, Tschöp MH, Müller TD. [Incretin-based co- and tri-agonists : Innovative polypharmacology for the treatment of obesity and diabetes]. Internist (Berl) 2019;60:895-902. [PMID: 31346639 DOI: 10.1007/s00108-019-0649-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
143 Petroni ML, Montesi L, Colosimo S, Caletti MT, Mazzotti A, Marchesini G. Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. Endocrinol Diabetes Metab 2019;2:e00082. [PMID: 31592154 DOI: 10.1002/edm2.82] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
144 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28. [PMID: 32039382 DOI: 10.1016/j.jhepr.2019.07.002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 148] [Article Influence: 46.3] [Reference Citation Analysis]
145 Clemmensen C, Finan B, Müller TD, DiMarchi RD, Tschöp MH, Hofmann SM. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat Rev Endocrinol 2019;15:90-104. [PMID: 30446744 DOI: 10.1038/s41574-018-0118-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
146 Lim JJ, Poppitt SD. How Satiating Are the 'Satiety' Peptides: A Problem of Pharmacology versus Physiology in the Development of Novel Foods for Regulation of Food Intake. Nutrients 2019;11:E1517. [PMID: 31277416 DOI: 10.3390/nu11071517] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
147 Boutari C, Polyzos SA, Mantzoros CS. Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it? Metabolism 2019;96:vi-xi. [DOI: 10.1016/j.metabol.2019.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
148 Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med 2019;154:86-92. [PMID: 31228775 DOI: 10.1016/j.rmed.2019.06.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
149 Wang C, Yang C, Chen YC, Ma L, Huang K. Rational Design of Hybrid Peptides: A Novel Drug Design Approach. Curr Med Sci 2019;39:349-55. [PMID: 31209802 DOI: 10.1007/s11596-019-2042-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
150 Almarshad F. Short-term monotherapy with Liraglutide for weight management: A case study. J Family Med Prim Care 2019;8:1804-6. [PMID: 31198765 DOI: 10.4103/jfmpc.jfmpc_213_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
151 Anholm C, Kumarathurai P, Jürs A, Pedersen LR, Nielsen OW, Kristiansen OP, Fenger M, Holst JJ, Madsbad S, Sajadieh A, Haugaard SB. Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Diabetol Metab Syndr 2019;11:42. [PMID: 31164926 DOI: 10.1186/s13098-019-0438-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
152 Nolen-doerr E, Stockman M, Rizo I. Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. Curr Obes Rep 2019;8:284-91. [DOI: 10.1007/s13679-019-00350-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
153 Niezen S, Diaz Del Castillo H, Mendez Castaner LA, Fornoni A. Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. Endocrinol Diabetes Metab 2019;2:e00072. [PMID: 31294086 DOI: 10.1002/edm2.72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 de Lusignan S, Hinton W, Konstantara E, Munro N, Whyte M, Mount J, Feher M. Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol). BMC Health Serv Res 2019;19:284. [PMID: 31053136 DOI: 10.1186/s12913-019-4112-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
155 Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev 2019;20:816-28. [PMID: 30972878 DOI: 10.1111/obr.12841] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 23.0] [Reference Citation Analysis]
156 Jung CH, Mok JO. The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. J Obes Metab Syndr 2019;28:18-29. [PMID: 31089576 DOI: 10.7570/jomes.2019.28.1.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
157 He Y, Haynes W, Meyers CD, Amer A, Zhang Y, Mahling P, Mendonza AE, Ma S, Chutkow W, Bachman E. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab 2019;21:1311-21. [DOI: 10.1111/dom.13654] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 14.7] [Reference Citation Analysis]
158 Kyriachenko Y, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes 2019; 10(3): 154-168 [PMID: 30891151 DOI: 10.4239/wjd.v10.i3.154] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 15.0] [Reference Citation Analysis]
159 Park SH, Yoon JH, Seo DY, Kim TN, Ko JR, Han J. Resistance Exercise Training Attenuates the Loss of Endogenous GLP-1 Receptor in the Hypothalamus of Type 2 Diabetic Rats. Int J Environ Res Public Health 2019;16:E830. [PMID: 30866463 DOI: 10.3390/ijerph16050830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
160 Babenko AY, Savitskaya DA, Kononova YA, Trofimova AY, Simanenkova AV, Vasilyeva EY, Shlyakhto EV. Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity. J Diabetes Res 2019;2019:1365162. [PMID: 30944827 DOI: 10.1155/2019/1365162] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
161 Järvinen A, Laine MK, Tikkanen R, Castrén ML. Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism. Front Psychiatry 2019;10:97. [PMID: 30881319 DOI: 10.3389/fpsyt.2019.00097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
162 Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect 2019;8:195-202. [PMID: 30707677 DOI: 10.1530/EC-18-0514] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
163 Tardio V, Kellett S, Bidal-st-aubin M, Tsoukas MA. Effects of incretin therapy and bariatric surgery on inflammation in obese patients. Obesity Medicine 2019;13:13-20. [DOI: 10.1016/j.obmed.2018.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haelst MM, ter Horst KW, Serlie MJ. The pathogenesis of obesity. Metabolism 2019;92:26-36. [DOI: 10.1016/j.metabol.2018.12.012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 24.3] [Reference Citation Analysis]
165 Wiciński M, Socha M, Malinowski B, Wódkiewicz E, Walczak M, Górski K, Słupski M, Pawlak-Osińska K. Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events. Int J Mol Sci 2019;20:E1050. [PMID: 30823403 DOI: 10.3390/ijms20051050] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
166 Zobel EH, von Scholten BJ, Goldman B, Persson F, Hansen TW, Rossing P. Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. Diabetes Obes Metab 2019;21:1261-5. [PMID: 30663196 DOI: 10.1111/dom.13638] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
167 Bistola V, Lambadiari V, Dimitriadis G, Ioannidis I, Makrilakis K, Tentolouris N, Tsapas A, Parissis J. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. Heart Fail Rev 2018;23:377-88. [PMID: 29383638 DOI: 10.1007/s10741-018-9674-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
168 Guo H, Ma C, Zheng W, Luo Y, Li C, Li X, Ma X, Feng C, Zhang T, Han Y, Luo Z, Zhan Y, Li R, Wang L, Jiang J. Dual‐Stimuli‐Responsive Gut Microbiota‐Targeting Berberine‐CS/PT‐NPs Improved Metabolic Status in Obese Hamsters. Adv Funct Mater 2019;29:1808197. [DOI: 10.1002/adfm.201808197] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
169 Gurova OY, Fadeev VV, Maloletkina ES. Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence. Diabetes mellitus 2019;21:524-533. [DOI: 10.14341/dm9603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Raya PM, Blasco FJA, Hunt B, Martin V, Thorsted BL, Basse A, Price H. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes Obes Metab 2019;21:1349-56. [PMID: 30740861 DOI: 10.1111/dom.13660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
171 O’gorman CS, Scully P, O’sullivan D, Cauchi J, Daneman D, Hamilton JK. The Future Directions of Childhood Obesity and Clinical Management. Global Perspectives on Childhood Obesity 2019. [DOI: 10.1016/b978-0-12-812840-4.00034-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
172 Jenkins AJ, Scott E, Fulcher J, Kilov G, Januszewski AS. Management of Diabetes Mellitus. Contemporary Cardiology 2019. [DOI: 10.1007/978-3-319-97622-8_7] [Reference Citation Analysis]
173 Van Name MA. Medications for the Treatment of Type II Diabetes. Pediatric Type II Diabetes 2019. [DOI: 10.1016/b978-0-323-55138-0.00012-7] [Reference Citation Analysis]
174 Gonzalez-campoy JM. Hormonal Regulation of Energy Balance and Energy Stores. Bariatric Endocrinology 2019. [DOI: 10.1007/978-3-319-95655-8_3] [Reference Citation Analysis]
175 Keegan MT. Endocrine Pharmacology. Pharmacology and Physiology for Anesthesia 2019. [DOI: 10.1016/b978-0-323-48110-6.00036-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
176 Jain M, Carlson G, Cook W, Morrow L, Petrone M, White NE, Wang T, Naylor J, Ambery P, Lee C, Hirshberg B. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus. Diabetologia 2019;62:373-86. [DOI: 10.1007/s00125-018-4789-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
177 Tikhonenko EV, Arkhipova AG, Babenko AY, Shlyakhto EV. Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity. Klin med 2018;96:746-753. [DOI: 10.18821/0023-2149-2018-96-8-746-753] [Reference Citation Analysis]
178 Brandt SJ, Götz A, Tschöp MH, Müller TD. Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 2018;100:190-201. [PMID: 29412819 DOI: 10.1016/j.peptides.2017.12.021] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 19.3] [Reference Citation Analysis]
179 Andrikou E, Tsioufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N. GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic J Cardiol. 2018;. [PMID: 30528435 DOI: 10.1016/j.hjc.2018.11.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
180 Gomez-peralta F, Escalada San Martín FJ, Menéndez Torre E, Mata Cases M, Ferrer García JC, Ezkurra Loiola P, Ávila Lachica L, Fornos Pérez JA, Artola Menéndez S, Álvarez-guisasola F, Rica Echevarría I, Girbés Borrás J. Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018. Endocrinología, Diabetes y Nutrición 2018;65:611-24. [DOI: 10.1016/j.endinu.2018.08.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
181 Gomez-peralta F, Escalada San Martín FJ, Menéndez Torre E, Mata Cases M, Ferrer García JC, Ezkurra Loiola P, Ávila Lachica L, Fornos Pérez JA, Artola Menéndez S, Álvarez-guisasola F, Rica Echevarría I, Girbés Borrás J. Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update. Endocrinología, Diabetes y Nutrición (English ed ) 2018;65:611-624. [DOI: 10.1016/j.endien.2018.11.010] [Reference Citation Analysis]
182 Tofé S, Argüelles I, Mena E, Serra G, Codina M, Urgeles JR, García H, Pereg V. Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study. Endocrinol Diabetes Metab 2019;2:e00051. [PMID: 30815578 DOI: 10.1002/edm2.51] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
183 . Clinical and Investigative Endocrinology and Diabetes. Endocr Pract 2018;24 Suppl 2:1-22. [PMID: 30430841 DOI: 10.4158/1934-2403-24.s2.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
184 Hulst AH, Plummer MP, Hollmann MW, DeVries JH, Preckel B, Deane AM, Hermanides J. Systematic review of incretin therapy during peri-operative and intensive care. Crit Care 2018;22:299. [PMID: 30428906 DOI: 10.1186/s13054-018-2197-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
185 Hirota Y, Matsuda T, Nakajima S, Takabe M, Hashimoto N, Nakamura T, Okada Y, Sakaguchi K, Ogawa W. Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance. Endocrine 2019;64:43-7. [PMID: 30406884 DOI: 10.1007/s12020-018-1808-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
186 Sheriba N, Samy M, Adel C, Anas S. Relationship between glucagon like peptide-1 and non-alcoholic fatty liver disease in diabetic and non-diabetic patients. Diabetes Metab Syndr 2019;13:526-9. [PMID: 30641759 DOI: 10.1016/j.dsx.2018.11.024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, Mantzoros CS. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019;92:170-92. [PMID: 30391259 DOI: 10.1016/j.metabol.2018.10.010] [Cited by in Crossref: 110] [Cited by in F6Publishing: 119] [Article Influence: 27.5] [Reference Citation Analysis]
188 Liakos A, Lambadiari V, Bargiota A, Kitsios K, Avramidis I, Kotsa K, Gerou S, Boura P, Tentolouris N, Dimitriadis G, Tsapas A. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2019;21:517-24. [DOI: 10.1111/dom.13541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
189 Bifari F, Manfrini R, Dei Cas M, Berra C, Siano M, Zuin M, Paroni R, Folli F. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res 2018;137:219-29. [PMID: 30359962 DOI: 10.1016/j.phrs.2018.09.025] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
190 Petunina NA, Telnova MЕ. Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes. Diabetes mellitus 2018;21:293-300. [DOI: 10.14341/dm9623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
191 Siskind D, Hahn M, Correll CU, Fink-jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. Diabetes Obes Metab 2019;21:293-302. [DOI: 10.1111/dom.13522] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
192 Morse C, Sze D, Patel D, Goldman J. Nonglycemic Outcomes of Antidiabetic Medications. Clin Diabetes 2019;37:131-41. [PMID: 31057219 DOI: 10.2337/cd18-0015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Yin TT, Bi Y, Li P, Shen SM, Wang WM, Jiang C, Gao CX, Wang Y, Gao LJ, Zhu DL, Feng WH. Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. Nutr Metab (Lond) 2018;15:67. [PMID: 30302121 DOI: 10.1186/s12986-018-0295-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
194 Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, Einig C, Keil S, Haack T, Wagner M, Bossart M, Larsen PJ. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab 2019;21:120-8. [PMID: 30091218 DOI: 10.1111/dom.13494] [Cited by in Crossref: 94] [Cited by in F6Publishing: 101] [Article Influence: 23.5] [Reference Citation Analysis]
195 Namekawa J, Nemoto S, Sunada G, Takanashi Y, Fujio S, Shirai M, Asai F. Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist. J Vet Med Sci 2018;80:1515-23. [PMID: 30175725 DOI: 10.1292/jvms.18-0306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
196 Qian D, Zhang T, Tan X, Zheng P, Liang Z, Xie J, Jiang J, Situ B. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. PLoS One 2018;13:e0202563. [PMID: 30148851 DOI: 10.1371/journal.pone.0202563] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
197 Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, Gao LJ, Yang DH, Zhu DL. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. J Diabetes Investig. 2019;10:399-407. [PMID: 29957886 DOI: 10.1111/jdi.12888] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
198 Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Renal Physiol 2018;315:F1519-25. [PMID: 30110568 DOI: 10.1152/ajprenal.00211.2018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
199 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018;24:3361-73. [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 258] [Cited by in F6Publishing: 264] [Article Influence: 64.5] [Reference Citation Analysis]
200 Blonde L, Dipp S, Cadena D. Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. Adv Ther 2018;35:939-65. [PMID: 29777519 DOI: 10.1007/s12325-018-0694-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
201 Vergès B, Charbonnel B. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Diabetes Metab 2017;43 Suppl 1:2S3-2S12. [PMID: 28431669 DOI: 10.1016/S1262-3636(17)30067-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
202 Ishihara H, Yamaguchi S, Nakao I, Sakatani T. Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study. Diabetes Ther 2018;9:1549-67. [PMID: 29926400 DOI: 10.1007/s13300-018-0455-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
203 Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB;  LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018;41:1663-1671. [PMID: 29898902 DOI: 10.2337/dc17-1825] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
204 Meyer-Gerspach AC, Ly HG, Borgwardt S, Dupont P, Beglinger C, Van Oudenhove L, Wölnerhanssen BK. Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: A pilotstudy. Diabetes Obes Metab 2018;20:2330-8. [PMID: 29790260 DOI: 10.1111/dom.13369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
205 Mubarak HA, Mahmoud MM, Shoukry HS, Merzeban DH, Sayed SS, Rashed LA. Protective effects of melatonin and glucagon-like peptide-1 receptor agonist (liraglutide) on gastric ischaemia-reperfusion injury in high-fat/sucrose-fed rats. Clin Exp Pharmacol Physiol 2018;45:934-42. [DOI: 10.1111/1440-1681.12956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
206 Rix I, Steen Pedersen J, Storgaard H, Gluud LL. Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. Clin Physiol Funct Imaging 2019;39:122-7. [PMID: 29808958 DOI: 10.1111/cpf.12526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Zhao L, Chen Y, Xia F, Abudukerimu B, Zhang W, Guo Y, Wang N, Lu Y. A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. Front Endocrinol (Lausanne). 2018;9:233. [PMID: 29867765 DOI: 10.3389/fendo.2018.00233] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 14.0] [Reference Citation Analysis]
208 Scuderi MA, Ribeiro Petito M, Unniappan S, Waldner C, Mehain S, McMillian CJ, Snead EC. Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus. Domest Anim Endocrinol 2018;65:80-9. [PMID: 30015124 DOI: 10.1016/j.domaniend.2018.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
209 Yildirim Simsir I, Soyaltin UE, Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2018;12:469-75. [DOI: 10.1016/j.dsx.2018.03.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
210 van Baar ACG, Prodan A, Wahlgren CD, Poulsen SS, Knop FK, Groen AK, Bergman JJ, Nieuwdorp M, Levin E. Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolites. Endocr Connect 2018;7:673-80. [PMID: 29669802 DOI: 10.1530/EC-18-0094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
211 Kapeluto J, Tchernof A, Biertho L. Surgery for Diabetes: Clinical and Mechanistic Aspects. Can J Diabetes 2017;41:392-400. [PMID: 28739097 DOI: 10.1016/j.jcjd.2017.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
212 Mulvaney CA, Duarte GS, Menon S, Handley J, Emsley HC; Cochrane Movement Disorders Group. GLP-1 receptor agonists for Parkinson's disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
213 Basolo A, Burkholder J, Osgood K, Graham A, Bundrick S, Frankl J, Piaggi P, Thearle MS, Krakoff J. Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial. Metabolism 2018;85:116-25. [PMID: 29596853 DOI: 10.1016/j.metabol.2018.03.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
214 Mella R, Schmidt CB, Romagnoli PP, Teske JA, Perez-Leighton C. The Food Environment, Preference, and Experience Modulate the Effects of Exendin-4 on Food Intake and Reward. Obesity (Silver Spring) 2017;25:1844-51. [PMID: 29086500 DOI: 10.1002/oby.21939] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
215 Wismann P, Pedersen SL, Hansen G, Mannerstedt K, Pedersen PJ, Jeppesen PB, Vrang N, Fosgerau K, Jelsing J. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. Physiol Behav 2018;192:72-81. [PMID: 29540315 DOI: 10.1016/j.physbeh.2018.03.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
216 Lally J, O’ Loughlin A, Stubbs B, Guerandel A, O’shea D, Gaughran F. Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. Expert Review of Clinical Pharmacology 2018;11:411-24. [DOI: 10.1080/17512433.2018.1445968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
217 Oktay AA, Akturk HK, Esenboğa K, Javed F, Polin NM, Jahangir E. Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. Current Problems in Cardiology 2018;43:68-110. [DOI: 10.1016/j.cpcardiol.2017.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
218 Jia X, Alam M, Ye Y, Bajaj M, Birnbaum Y. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther 2018;32:65-72. [DOI: 10.1007/s10557-018-6773-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
219 Sever MJ, Ferjan S, Janez A. Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome. Debatable Topics in PCOS Patients 2018. [DOI: 10.5772/intechopen.70648] [Reference Citation Analysis]
220 Nassif M, Kosiborod M. Effect of glucose-lowering therapies on heart failure. Nat Rev Cardiol 2018;15:282-91. [DOI: 10.1038/nrcardio.2017.211] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
221 Morgan CL, Qiao Q, Grandy S, Johnsson K, Jenkins-Jones S, Holden S, Currie CJ. Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study. Diabetes Ther 2018;9:269-83. [PMID: 29318537 DOI: 10.1007/s13300-017-0359-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
222 Kelly AS, Fox CK. Role of Pharmacotherapy in the Treatment of Pediatric Obesity and Its Comorbidities. Contemporary Endocrinology 2018. [DOI: 10.1007/978-3-319-68192-4_35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
223 Anandhakrishnan A, Korbonits M. Glucagon-Like Peptide 1 and Human Obesity. Practical Guide to Obesity Medicine 2018. [DOI: 10.1016/b978-0-323-48559-3.00003-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
224 Page LC, Miller MD, D’alessio D, Tong J. Gastrointestinal Hormones and the Control of Food Intake and Energy Metabolism. Contemporary Endocrinology 2018. [DOI: 10.1007/978-3-319-68192-4_3] [Reference Citation Analysis]
225 Waldrop G, Zhong J, Peters M, Goud A, Chen Y, Davis SN, Mukherjee B, Rajagopalan S. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis. Journal of Diabetes and its Complications 2018;32:113-22. [DOI: 10.1016/j.jdiacomp.2016.08.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
226 Velojić-golubović M. LIRAGLUTIDE AND INSULIN DETEMIR IN COMBINATION - A NEW THERAPEUTIC OPTION IN PATIENTS WITH TYPE 2 DIABETES: A CASE REPORT. amm 2017;56:132-137. [DOI: 10.5633/amm.2017.0421] [Reference Citation Analysis]
227 Scott RA, Freitag DF, Li L, Chu AY, Surendran P, Young R, Grarup N, Stancáková A, Chen Y, Varga TV, Yaghootkar H, Luan J, Zhao JH, Willems SM, Wessel J, Wang S, Maruthur N, Michailidou K, Pirie A, van der Lee SJ, Gillson C, Al Olama AA, Amouyel P, Arriola L, Arveiler D, Aviles-Olmos I, Balkau B, Barricarte A, Barroso I, Garcia SB, Bis JC, Blankenberg S, Boehnke M, Boeing H, Boerwinkle E, Borecki IB, Bork-Jensen J, Bowden S, Caldas C, Caslake M, Cupples LA, Cruchaga C, Czajkowski J, den Hoed M, Dunn JA, Earl HM, Ehret GB, Ferrannini E, Ferrieres J, Foltynie T, Ford I, Forouhi NG, Gianfagna F, Gonzalez C, Grioni S, Hiller L, Jansson JH, Jørgensen ME, Jukema JW, Kaaks R, Kee F, Kerrison ND, Key TJ, Kontto J, Kote-Jarai Z, Kraja AT, Kuulasmaa K, Kuusisto J, Linneberg A, Liu C, Marenne G, Mohlke KL, Morris AP, Muir K, Müller-Nurasyid M, Munroe PB, Navarro C, Nielsen SF, Nilsson PM, Nordestgaard BG, Packard CJ, Palli D, Panico S, Peloso GM, Perola M, Peters A, Poole CJ, Quirós JR, Rolandsson O, Sacerdote C, Salomaa V, Sánchez MJ, Sattar N, Sharp SJ, Sims R, Slimani N, Smith JA, Thompson DJ, Trompet S, Tumino R, van der A DL, van der Schouw YT, Virtamo J, Walker M, Walter K, Abraham JE, Amundadottir LT, Aponte JL, Butterworth AS, Dupuis J, Easton DF, Eeles RA, Erdmann J, Franks PW, Frayling TM, Hansen T, Howson JM, Jørgensen T, Kooner J, Laakso M, Langenberg C, McCarthy MI, Pankow JS, Pedersen O, Riboli E, Rotter JI, Saleheen D, Samani NJ, Schunkert H, Vollenweider P, O'Rahilly S, Deloukas P, Danesh J, Goodarzi MO, Kathiresan S, Meigs JB, Ehm MG, Wareham NJ, Waterworth DM; CVD50 consortium., GERAD_EC Consortium., Neurology Working Group of the Cohorts for Heart., Aging Research in Genomic Epidemiology (CHARGE)., Alzheimer’s Disease Genetics Consortium., Pancreatic Cancer Cohort Consortium., European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD)., EPIC-InterAct., CHARGE consortium., CHD Exome+ Consortium., CARDIOGRAM Exome Consortium. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci Transl Med 2016;8:341ra76. [PMID: 27252175 DOI: 10.1126/scitranslmed.aad3744] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 16.0] [Reference Citation Analysis]
228 Tong L, Pan C, Wang H, Bertolini M, Lew E, Meneghini LF. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database. Diabetes Obes Metab 2018;20:831-9. [PMID: 29119712 DOI: 10.1111/dom.13156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
229 Rives-lange C, Ait Boudaoud A, Czernichow S, Carette C. Les traitements médicamenteux de l’obésité. Acta Endosc 2017;47:304-309. [DOI: 10.1007/s10190-017-0636-3] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
230 Farey JE, Preda TC, Fisher OM, Levert-Mignon AJ, Stewart RL, Karsten E, Herbert BR, Swarbrick MM, Lord RV. Effect of Laparoscopic Sleeve Gastrectomy on Fasting Gastrointestinal, Pancreatic, and Adipose-Derived Hormones and on Non-Esterified Fatty Acids. Obes Surg. 2017;27:399-407. [PMID: 27465935 DOI: 10.1007/s11695-016-2302-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
231 Kelly AS, Fox CK. Pharmacotherapy in the Management of Pediatric Obesity. Curr Diab Rep 2017;17:55. [PMID: 28646356 DOI: 10.1007/s11892-017-0886-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
232 Coveleskie K, Kilpatrick LA, Gupta A, Stains J, Connolly L, Labus JS, Sanmiguel C, Mayer EA. The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. Obes Sci Pract 2017;3:434-45. [PMID: 29259802 DOI: 10.1002/osp4.124] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
233 Götz A, Jall S, Tschöp MH, Müller TD. Inkretinbasierte Medikamente zur Diabetes- und Adipositastherapie. Diabetologe 2017;13:505-513. [DOI: 10.1007/s11428-017-0267-x] [Reference Citation Analysis]
234 Ritzel RA. Adipositas und Prädiabetes. Diabetologe 2017;13:482-486. [DOI: 10.1007/s11428-017-0274-y] [Reference Citation Analysis]
235 Lee-barkey YH, Stratmann B, Tschöpe D. Inkretinbasierte Diabetesmedikamente. Diabetologe 2017;13:498-504. [DOI: 10.1007/s11428-017-0269-8] [Reference Citation Analysis]
236 Benaiges D, Pedro-botet J, Flores-le Roux JA, Climent E, Goday A. Past, present and future of pharmacotherapy for obesity. Clínica e Investigación en Arteriosclerosis (English Edition) 2017;29:256-264. [DOI: 10.1016/j.artere.2017.06.003] [Reference Citation Analysis]
237 Galstyan GR, Shestakova EA, Sklyanik IA. Obesity and type 2 diabetes: can we find a compromised treatment solution? Diabetes mellitus 2017;20:270-278. [DOI: 10.14341/dm8726] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
238 Marya, Khan H, Nabavi SM, Habtemariam S. Anti-diabetic potential of peptides: Future prospects as therapeutic agents. Life Sci 2018;193:153-8. [PMID: 29055800 DOI: 10.1016/j.lfs.2017.10.025] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
239 Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA 2017;318:1460-70. [PMID: 29049653 DOI: 10.1001/jama.2017.14752] [Cited by in Crossref: 220] [Cited by in F6Publishing: 227] [Article Influence: 44.0] [Reference Citation Analysis]
240 Montandon SA, Jornayvaz FR. Effects of Antidiabetic Drugs on Gut Microbiota Composition. Genes (Basel). 2017;8:250. [PMID: 28973971 DOI: 10.3390/genes8100250] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 12.4] [Reference Citation Analysis]
241 Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes 2017;10:403-12. [PMID: 29033597 DOI: 10.2147/DMSO.S141235] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
242 Kleinert M, Clemmensen C, Stemmer K, Müller TD, Dimarchi RD, Tschöp MH. Emerging Poly-Agonists for Obesity and Type 2 Diabetes: Emerging Poly-Agonists for Obesity. Obesity 2017;25:1647-9. [DOI: 10.1002/oby.21932] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
243 Shah M, Hurt RT, Mundi MS. Phenotypes of Obesity: How it Impacts Management. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0598-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
244 Benaiges D, Pedro-botet J, Flores-le Roux JA, Climent E, Goday A. Pasado, presente y futuro de la farmacoterapia para la obesidad. Clínica e Investigación en Arteriosclerosis 2017;29:256-64. [DOI: 10.1016/j.arteri.2017.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
245 Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol 2018;6:237-48. [PMID: 28919062 DOI: 10.1016/S2213-8587(17)30236-X] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 25.8] [Reference Citation Analysis]
246 Hieng YC. An Internal Audit of Diabetes Care for Type 2 Diabetic Patients in a Public Hospital Diabetes Clinic in Malaysia. Malays J Med Sci 2017;24:55-60. [PMID: 28894404 DOI: 10.21315/mjms2017.24.2.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
247 Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017;13:2231-41. [PMID: 28883731 DOI: 10.2147/NDT.S113099] [Cited by in Crossref: 129] [Cited by in F6Publishing: 140] [Article Influence: 25.8] [Reference Citation Analysis]
248 Levin P, Fan T, Song X, Nero D, Davis B, Chu BC. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE. Endocr Pract 2017;23:1316-24. [PMID: 28816532 DOI: 10.4158/EP171769.OR] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
249 Genovese S, Mannucci E, Ceriello A. A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. Adv Ther 2017;34:1791-814. [PMID: 28674957 DOI: 10.1007/s12325-017-0499-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
250 Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, Polonsky WH. Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. Obes Sci Pract 2017;3:342-51. [PMID: 29071110 DOI: 10.1002/osp4.116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
251 Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done? Diabetes Obes Metab. 2017;19:1655-1668. [PMID: 28509408 DOI: 10.1111/dom.13009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 10.4] [Reference Citation Analysis]
252 Kautzky-Willer A, Harreiter J. Sex and gender differences in therapy of type 2 diabetes. Diabetes Res Clin Pract 2017;131:230-41. [PMID: 28779681 DOI: 10.1016/j.diabres.2017.07.012] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
253 Srikanth S, Deedwania P. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. Curr Hypertens Rep 2016;18:76. [PMID: 27730495 DOI: 10.1007/s11906-016-0683-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
254 Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, DiMarchi RD. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metab 2016;24:51-62. [PMID: 27411008 DOI: 10.1016/j.cmet.2016.06.021] [Cited by in Crossref: 166] [Cited by in F6Publishing: 168] [Article Influence: 33.2] [Reference Citation Analysis]
255 Ruyatkina LA, Sorokin M. Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance. Diabetes mellitus 2017;20:142-150. [DOI: 10.14341/7875] [Reference Citation Analysis]
256 Sarafidis PA, Alexandrou ME, Ruilope LM. A review of chemical therapies for treating diabetic hypertension. Expert Opinion on Pharmacotherapy 2017;18:909-23. [DOI: 10.1080/14656566.2017.1328054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
257 Geloneze B, de Lima-Júnior JC, Velloso LA. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis. Drugs 2017;77:493-503. [PMID: 28233273 DOI: 10.1007/s40265-017-0706-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
258 Wang W, Gao Y, Chen D, Wang C, Feng X, Ran X. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2017;129:213-223. [PMID: 28552612 DOI: 10.1016/j.diabres.2017.05.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
259 Nylander M, Frøssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online 2017;35:121-7. [PMID: 28479118 DOI: 10.1016/j.rbmo.2017.03.023] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
260 Lu Z, Yeung CK, Lin G, Yew DTW, Andrews PLR, Rudd JA. Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea. Neuropeptides 2017;65:28-36. [PMID: 28456436 DOI: 10.1016/j.npep.2017.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
261 Knop FK, Brønden A, Vilsbøll T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother 2017;18:555-71. [PMID: 28085521 DOI: 10.1080/14656566.2017.1282463] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
262 Wysham CH, Lin J, Kuritzky L. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. Postgrad Med 2017;129:436-45. [PMID: 28294702 DOI: 10.1080/00325481.2017.1297669] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
263 Drab SR. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy. Curr Diabetes Rev 2016;12:403-13. [PMID: 26694823 DOI: 10.2174/1573399812666151223093841] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
264 Luconi M, Cantini G, Ceriello A, Mannucci E. Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. Int J Cardiol 2017;241:302-10. [PMID: 28285800 DOI: 10.1016/j.ijcard.2017.02.126] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
265 Kirk SF, Shamliyan TA, Middleton M. Glucagon-like peptide-1 agonists for weight loss in people with obesity. Obesity Medicine 2017;5:29-43. [DOI: 10.1016/j.obmed.2017.01.003] [Reference Citation Analysis]
266 Lecube A, Monereo S, Rubio MÁ, Martínez-de-icaya P, Martí A, Salvador J, Masmiquel L, Goday A, Bellido D, Lurbe E, García-almeida JM, Tinahones FJ, García-luna PP, Palacio E, Gargallo M, Bretón I, Morales-conde S, Caixàs A, Menéndez E, Puig-domingo M, Casanueva FF. Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity. Endocrinología, Diabetes y Nutrición (English ed ) 2017;64:15-22. [DOI: 10.1016/j.endien.2017.03.007] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
267 Lecube A, Monereo S, Rubio MÁ, Martínez-de-icaya P, Martí A, Salvador J, Masmiquel L, Goday A, Bellido D, Lurbe E, García-almeida JM, Tinahones FJ, García-luna PP, Palacio E, Gargallo M, Bretón I, Morales-conde S, Caixàs A, Menéndez E, Puig-domingo M, Casanueva FF. Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad Española para el Estudio de la Obesidad de 2016. Endocrinología, Diabetes y Nutrición 2017;64:15-22. [DOI: 10.1016/j.endonu.2016.07.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 8.6] [Reference Citation Analysis]
268 Vergès B. Hypothèses mécanistiques pouvant expliquer les effets cardiovasculaires observés avec les inhibiteurs de SGLT2 et les agonistes des récepteurs du GLP-1. Médecine des Maladies Métaboliques 2017;11:2S37-2S42. [DOI: 10.1016/s1957-2557(17)30055-x] [Reference Citation Analysis]
269 Anholm C, Kumarathurai P, Pedersen LR, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. Diabetes Obes Metab 2017;19:850-7. [PMID: 28124822 DOI: 10.1111/dom.12891] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
270 Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017;19:524-36. [DOI: 10.1111/dom.12849] [Cited by in Crossref: 224] [Cited by in F6Publishing: 240] [Article Influence: 44.8] [Reference Citation Analysis]
271 Pastel E, Mcculloch L, Ward R, Joshi S, Gooding K, Shore A, Kos K. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Clinical Science 2017;131:343-53. [DOI: 10.1042/cs20160803] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
272 Sfera A, Osorio C, Inderias LA, Parker V, Price AI, Cummings M. The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients. Front Psychiatry 2017;8:20. [PMID: 28243210 DOI: 10.3389/fpsyt.2017.00020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
273 Janez A, Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloska 7, 1525 Ljubljana, Slovenia, Jensterle M. Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome. JDO 2017;4:1-3. [DOI: 10.15436/2376-0494.17.1246] [Reference Citation Analysis]
274 Sekar R, Wang L, Chow BK. Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides. Front Endocrinol (Lausanne) 2017;8:18. [PMID: 28223965 DOI: 10.3389/fendo.2017.00018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
275 Kaliora AC, Kanellos PT, Gioxari A, Karathanos VT. Regulation of GIP and Ghrelin in Healthy Subjects Fed on Sun-Dried Raisins: A Pilot Study with a Crossover Trial Design. J Med Food 2017;20:301-8. [PMID: 28170279 DOI: 10.1089/jmf.2016.0123] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
276 Gastaldelli A, Gaggini M. Response to: Drug therapy for ectopic fat: myth or reality? Expert Review of Cardiovascular Therapy 2017;15:73-74. [DOI: 10.1080/14779072.2017.1274234] [Reference Citation Analysis]
277 Jensterle M, Kravos NA, Goričar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 2017;17:5. [PMID: 28143456 DOI: 10.1186/s12902-017-0155-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
278 Nylander M, Frøssing S, Kistorp C, Faber J, Skouby SO. Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocr Connect 2017;6:89-99. [PMID: 28119323 DOI: 10.1530/EC-16-0113] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
279 Wei W, Buysman E, Grabner M, Xie L, Brekke L, Ke X, Chu JW, Levin PA. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies. Diabetes Obes Metab 2017;19:375-86. [PMID: 27860158 DOI: 10.1111/dom.12828] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
280 Oliveira J, Lau E, Carvalho D, Freitas P. Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports. J Med Case Rep 2017;11:12. [PMID: 28086952 DOI: 10.1186/s13256-016-1175-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
281 Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, Perfetti R, Blonde L. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol 2017;16:6. [PMID: 28086882 DOI: 10.1186/s12933-016-0490-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 15.2] [Reference Citation Analysis]
282 Dong Y, Lv Q, Li S, Wu Y, Li L, Li J, Zhang F, Sun X, Tong N. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:284-295. [PMID: 28065744 DOI: 10.1016/j.clinre.2016.11.009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 9.2] [Reference Citation Analysis]
283 Dagher A, Neseliler S, Han J. Appetite as Motivated Choice. Decision Neuroscience. Elsevier; 2017. pp. 397-409. [DOI: 10.1016/b978-0-12-805308-9.00032-4] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
284 Mannucci E, Monami M. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Adv Ther 2017;34:1-40. [PMID: 27844335 DOI: 10.1007/s12325-016-0432-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
285 Camilleri M, Abu Dayyeh B, Acosta A. The Management of Obesity. Metabolism and Pathophysiology of Bariatric Surgery 2017. [DOI: 10.1016/b978-0-12-804011-9.00003-0] [Reference Citation Analysis]
286 Zobel EH, von Scholten BJ, Lindhardt M, Persson F, Hansen TW, Rossing P. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. Journal of Diabetes and its Complications 2017;31:162-8. [DOI: 10.1016/j.jdiacomp.2016.09.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
287 Baek J, Kim BR, Hong JW, Kim SK, Jung JH, Jung J, Hahm JR. Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up. KMJ 2016;31:146-156. [DOI: 10.7180/kmj.2016.31.2.146] [Reference Citation Analysis]
288 Fu C, Jiang Y, Guo J, Su Z. Natural Products with Anti-obesity Effects and Different Mechanisms of Action. J Agric Food Chem 2016;64:9571-85. [DOI: 10.1021/acs.jafc.6b04468] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 16.7] [Reference Citation Analysis]
289 Martinussen C, Bojsen-Moller KN, Svane MS, Dejgaard TF, Madsbad S. Emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2017;22:87-99. [PMID: 27927032 DOI: 10.1080/14728214.2017.1269744] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
290 Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598 [PMID: 28031776 DOI: 10.4239/wjd.v7.i20.572] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
291 Vilsbøll T, Christensen M, Jorsal T, Knop FK. Non-Insulin Parenteral Therapies. Textbook of Diabetes 2016. [DOI: 10.1002/9781118924853.ch32] [Reference Citation Analysis]
292 Zhang Z, Liu H, Li Q. Glucagon-like peptide-1 effects lipotoxic oxidative stress by regulating the expression of microRNAs. Biochem Biophys Res Commun 2017;482:1462-8. [PMID: 27956176 DOI: 10.1016/j.bbrc.2016.12.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
293 Broglio F, Mannucci E, Napoli R, Nicolucci A, Purrello F, Nikonova E, Stager W, Trevisan R. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme. Diabetes Obes Metab 2017;19:248-56. [PMID: 27762096 DOI: 10.1111/dom.12810] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
294 Gastaldelli A, Gaggini M, Daniele G, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N, DeFronzo R, Iozzo P. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology 2016;64:2028-37. [PMID: 27639082 DOI: 10.1002/hep.28827] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
295 Sun H, Wang N, Cang Z, Zhu C, Zhao L, Nie X, Cheng J, Xia F, Zhai H, Lu Y. Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats. Obes Facts 2016;9:365-78. [PMID: 27898425 DOI: 10.1159/000449507] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 7.5] [Reference Citation Analysis]
296 Kajiwara M, Tanaka A, Kawasaki T, Nakao K, Sakamoto T, Toyoda S, Inoue T, Koga N, Node K. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. J Cardiol 2017;69:511-7. [PMID: 27894787 DOI: 10.1016/j.jjcc.2016.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
297 Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY, Ebdrup BH. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19:162-71. [PMID: 27717222 DOI: 10.1111/dom.12795] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
298 Mensberg P, Nyby S, Jørgensen PG, Storgaard H, Jensen MT, Sivertsen J, Holst JJ, Kiens B, Richter EA, Knop FK, Vilsbøll T. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes Obes Metab 2017;19:172-80. [PMID: 27717126 DOI: 10.1111/dom.12797] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
299 Gómez Huelgas R. Peso y diabetes tipo 2: nuevas recomendaciones. Medicina Clínica 2016;147:17-21. [DOI: 10.1016/s0025-7753(17)30620-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
300 Woo Baidal JA, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Sci Transl Med 2016;8:323rv1. [PMID: 26819197 DOI: 10.1126/scitranslmed.aad8390] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
301 Engelbrechtsen L, Iepsen EPW, Andersson EA, Mahendran Y, Lundgren J, Jonsson AE, Madsbad S, Holst JJ, Vestergaard H, Hansen T, Torekov SS. Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. Metabolomics 2016;12. [DOI: 10.1007/s11306-016-1128-0] [Reference Citation Analysis]
302 Lau DC, Teoh H. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes. Can J Diabetes. 2015;39 Suppl 5:S148-S154. [PMID: 26654858 DOI: 10.1016/j.jcjd.2015.09.090] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
303 Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis. J Hypertens. 2016;34:167-175. [PMID: 26682782 DOI: 10.1097/hjh.0000000000000782] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
304 Chang L, Kim MI. Antiglycemic Agents. Hospital Medicine Clinics 2016;5:542-554. [DOI: 10.1016/j.ehmc.2016.05.004] [Reference Citation Analysis]
305 Isaacs D, Prasad-reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. American Journal of Health-System Pharmacy 2016;73:1493-507. [DOI: 10.2146/ajhp150990] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
306 Lee EJ, Kim TN. Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. KJO 2016;25:121-8. [DOI: 10.7570/kjo.2016.25.3.121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
307 Hutch CR, Sandoval DA. Physiological and molecular responses to bariatric surgery: markers or mechanisms underlying T2DM resolution?: Bariatric surgery and type 2 diabetes. Ann N Y Acad Sci 2017;1391:5-19. [DOI: 10.1111/nyas.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
308 Waldrop G, Zhong J, Peters M, Rajagopalan S. Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know. J Am Coll Cardiol 2016;67:1488-96. [PMID: 27012410 DOI: 10.1016/j.jacc.2015.12.058] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
309 Wang L, Li P, Tang Z, Yan X, Feng B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep. 2016;6:33251. [PMID: 27633081 DOI: 10.1038/srep33251] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 13.5] [Reference Citation Analysis]
310 O'keeffe M. The importance of the multidisciplinary team for the management of complex obesity in patients with diabetes. Pract Diab 2016;33:253-256. [DOI: 10.1002/pdi.2046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
311 Su N, Li Y, Xu T, Li L, Kwong JS, Du H, Ren K, Li Q, Li J, Sun X, Li S, Tian H. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials. International Journal of Cardiology 2016;219:293-300. [DOI: 10.1016/j.ijcard.2016.06.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
312 Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs 2016;25:1167-79. [PMID: 27563838 DOI: 10.1080/13543784.2016.1221925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
313 Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Löfmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 2016;18:1176-90. [PMID: 27377054 DOI: 10.1111/dom.12735] [Cited by in Crossref: 142] [Cited by in F6Publishing: 150] [Article Influence: 23.7] [Reference Citation Analysis]
314 López-Ortiz MM, Garay-Sevilla ME, Tejero ME, Perez-Luque EL. Analysis of the interaction between transcription factor 7-like 2 genetic variants with nopal and wholegrain fibre intake: effects on anthropometric and metabolic characteristics in type 2 diabetes patients. Br J Nutr 2016;116:969-78. [PMID: 27480250 DOI: 10.1017/S0007114516002798] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
315 Vorsanger MH, Subramanyam P, Weintraub HS, Lamm SH, Underberg JA, Gianos E, Goldberg IJ, Schwartzbard AZ. Cardiovascular Effects of the New Weight Loss Agents. Journal of the American College of Cardiology 2016;68:849-59. [DOI: 10.1016/j.jacc.2016.06.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
316 Qiao Q, Johnsson K, Grandy S, Kostev K. Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany. J Diabetes Sci Technol 2017;11:272-7. [PMID: 27470665 DOI: 10.1177/1932296816661349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
317 Xue X, Ren Z, Zhang A, Yang Q, Zhang W, Liu F. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. Int J Clin Pract 2016;70:649-56. [PMID: 27456750 DOI: 10.1111/ijcp.12847] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
318 Sarraju A, Kim SH, Knowles JW. Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists. Curr Atheroscler Rep 2016;18:7. [PMID: 26782825 DOI: 10.1007/s11883-016-0558-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
319 Younk LM, Lamos EM, Davis SN. Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf 2016;15:1239-57. [PMID: 27268470 DOI: 10.1080/14740338.2016.1195368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
320 Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12:566-592. [PMID: 27339889 DOI: 10.1038/nrendo.2016.86] [Cited by in Crossref: 215] [Cited by in F6Publishing: 223] [Article Influence: 35.8] [Reference Citation Analysis]
321 Lin HV, Efanov AM, Fang X, Beavers LS, Wang X, Wang J, Gonzalez Valcarcel IC, Ma T. GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism. PLoS One 2016;11:e0157298. [PMID: 27322810 DOI: 10.1371/journal.pone.0157298] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
322 Gautier J, Martinez L, Penfornis A, Eschwège E, Charpentier G, Bouzidi A, Madani S, Gourdy P. Efficacité et taux de maintenance du liraglutide chez les patients diabétiques de type 2 en pratique clinique courante en France Étude EVIDENCE : Une étude observationnelle, prospective, post-commercialisation, avec un suivi de 2 ans. Médecine des Maladies Métaboliques 2016;10:341-347. [DOI: 10.1016/s1957-2557(16)30122-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
323 Hershon KS. Options for empagliflozin in combination therapy in type 2 diabetes mellitus. Int J Gen Med 2016;9:155-72. [PMID: 27307761 DOI: 10.2147/IJGM.S100288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
324 Curtis L, Humayun MA, Walker J, Hampton K, Partridge H. Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control. Pract Diab 2016;33:129-32. [DOI: 10.1002/pdi.2018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
325 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
326 Li L, Li S, Liu J, Deng K, Busse JW, Vandvik PO, Wong E, Sohani ZN, Bala MM, Rios LP, Malaga G, Ebrahim S, Shen J, Zhang L, Zhao P, Chen Q, Wang Y, Guyatt GH, Sun X. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord 2016;16:91. [PMID: 27169565 DOI: 10.1186/s12872-016-0260-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
327 López-lópez J, Di Stefano KA, Velásquez E, Camacho PA, López-jaramillo P. ¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica? Revista Colombiana de Cardiología 2016;23:200-9. [DOI: 10.1016/j.rccar.2015.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
328 de Wit HM, Te Groen M, Rovers MM, Tack CJ. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;82:301-14. [PMID: 26935973 DOI: 10.1111/bcp.12925] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
329 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 209] [Cited by in F6Publishing: 243] [Article Influence: 34.8] [Reference Citation Analysis]
330 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402. [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004] [Cited by in Crossref: 2086] [Cited by in F6Publishing: 1790] [Article Influence: 347.7] [Reference Citation Analysis]
331 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121-40. [DOI: 10.1007/s00125-016-3902-y] [Cited by in Crossref: 302] [Cited by in F6Publishing: 244] [Article Influence: 50.3] [Reference Citation Analysis]
332 May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7:69-83. [PMID: 27092232 DOI: 10.1177/2042018816638050] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
333 Qiao Q, Grandy S, Hiller J, Kostev K. Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany. PLoS One 2016;11:e0152281. [PMID: 27019360 DOI: 10.1371/journal.pone.0152281] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
334 Strain WD, Smith C. Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? Diabetes Ther 2016;7:175-85. [PMID: 27010644 DOI: 10.1007/s13300-016-0165-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
335 Skov J, Pedersen M, Holst JJ, Madsen B, Goetze JP, Rittig S, Jonassen T, Frøkiaer J, Dejgaard A, Christiansen JS. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 2016;18:581-9. [DOI: 10.1111/dom.12651] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 13.2] [Reference Citation Analysis]
336 Kuroki T, Tanaka R, Shimada Y, Yamashiro K, Ueno Y, Shimura H, Urabe T, Hattori N. Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice. Stroke 2016;47:1328-35. [PMID: 26979865 DOI: 10.1161/STROKEAHA.116.012934] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
337 Poudyal H. Mechanisms for the cardiovascular effects of glucagon-like peptide-1. Acta Physiol (Oxf) 2016;216:277-313. [PMID: 26384481 DOI: 10.1111/apha.12604] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
338 Schlögl H. GLP-1-Analogon zur Gewichtsreduktion. Diabetologe 2016;12:119-121. [DOI: 10.1007/s11428-016-0072-y] [Reference Citation Analysis]
339 Kayaniyil S, Lozano-Ortega G, Bennett HA, Johnsson K, Shaunik A, Grandy S, Kartman B. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. Diabetes Ther 2016;7:27-43. [PMID: 26886440 DOI: 10.1007/s13300-016-0155-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
340 Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study. Exp Ther Med 2016;11:1194-200. [PMID: 27073422 DOI: 10.3892/etm.2016.3081] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
341 Mayfield K, Siskind D, Winckel K, Russell AW, Kisely S, Smith G, Hollingworth S. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol 2016;30:227-36. [PMID: 26801056 DOI: 10.1177/0269881115625496] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
342 Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens) 2015;14:81-90. [PMID: 25885106 DOI: 10.1007/BF03401383] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
343 Ten Kulve JS, Veltman DJ, van Bloemendaal L, Groot PF, Ruhé HG, Barkhof F, Diamant M, Ijzerman RG. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. J Endocrinol 2016;229:1-12. [PMID: 26769912 DOI: 10.1530/JOE-15-0461] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
344 Østergaard L, Frandsen CS, Madsbad S. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Rev Clin Pharmacol 2016;9:241-65. [PMID: 26573176 DOI: 10.1586/17512433.2016.1121808] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
345 Verma A, Verma D. TREATMENT OF OBESITY: NEWER PERSPECTIVES. jemds 2016;5:112-113. [DOI: 10.14260/jemds/2016/27] [Reference Citation Analysis]
346 Ahima RS. Overview of Metabolic Syndrome. Metabolic Syndrome 2016. [DOI: 10.1007/978-3-319-11251-0_1] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
347 Cowley MA, Brown WA, Considine RV. Obesity. Endocrinology: Adult and Pediatric 2016. [DOI: 10.1016/b978-0-323-18907-1.00026-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
348 Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317-332. [PMID: 26511102 DOI: 10.1111/dom.12596] [Cited by in Crossref: 179] [Cited by in F6Publishing: 188] [Article Influence: 25.6] [Reference Citation Analysis]
349 Sharma AK, Thanikachalam PV, Rajput SK. Albiglutide: Is a better hope against diabetes mellitus? Biomed Pharmacother 2016;77:120-8. [PMID: 26796275 DOI: 10.1016/j.biopha.2015.12.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
350 Tomlinson B, Hu M, Zhang Y, Chan P, Liu Z. An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 2016;25:145-58. [DOI: 10.1517/13543784.2016.1123249] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
351 Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet 2016;293:509-15. [DOI: 10.1007/s00404-015-3976-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
352 Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H; Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts 2015;8:402-24. [PMID: 26641646 DOI: 10.1159/000442721] [Cited by in Crossref: 565] [Cited by in F6Publishing: 604] [Article Influence: 80.7] [Reference Citation Analysis]
353 Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, Albornos C, Moreno C, Cepeda M, Almodóvar F. An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes. BMC Endocr Disord 2015;15:78. [PMID: 26637348 DOI: 10.1186/s12902-015-0074-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
354 Gómez Huelgas R, Gómez Peralta F, Carrillo Fernández L, Galve E, Casanueva F, Puig Domingo M, Mediavilla Bravo J, Orozco Beltrán D, Muñoz JE, Menéndez Torre E, Artola Menendez S, Mazón Ramos P, Monereo Megías S, Caixas Pedrágos A, López Simarro F, Álvarez Guisasola F. Hacia un manejo integral del paciente con diabetes y obesidad. Posicionamiento de la SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC. Revista Clínica Española 2015;215:505-14. [DOI: 10.1016/j.rce.2015.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
355 Lau DC, Teoh H. Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes. Canadian Journal of Diabetes 2015;39:S134-41. [DOI: 10.1016/j.jcjd.2015.10.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
356 Gómez Huelgas R, Gómez Peralta F, Carrillo Fernández L, Galve E, Casanueva F, Puig Domingo M, Mediavilla Bravo J, Orozco Beltrán D, Ena Muñoz J, Menéndez Torre E, Artola Menendez S, Mazón Ramos P, Monereo Megías S, Caixas Pedrágos A, López Simarro F, Álvarez Guisasola F. Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC. Revista Clínica Española (English Edition) 2015;215:505-14. [DOI: 10.1016/j.rceng.2015.09.004] [Reference Citation Analysis]
357 de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour. Int J Clin Pharm 2016;38:144-51. [PMID: 26597956 DOI: 10.1007/s11096-015-0219-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
358 Guo XY, Liu J, Gao Y. Nonalcoholic fatty liver disease: Pathogenesis and incretin based therapies. Shijie Huaren Xiaohua Zazhi 2015; 23(31): 4990-4996 [DOI: 10.11569/wcjd.v23.i31.4990] [Reference Citation Analysis]
359 Acosta A, Camilleri M, Burton D, O'Neill J, Eckert D, Carlson P, Zinsmeister AR. Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Physiol Rep 2015;3:e12610. [PMID: 26542264 DOI: 10.14814/phy2.12610] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
360 Clemmensen C, Finan B, Fischer K, Tom RZ, Legutko B, Sehrer L, Heine D, Grassl N, Meyer CW, Henderson B, Hofmann SM, Tschöp MH, Van der Ploeg LH, Müller TD. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol Med 2015;7:288-98. [PMID: 25652173 DOI: 10.15252/emmm.201404508] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
361 Górriz JL, Nieto J, Navarro-González JF, Molina P, Martínez-Castelao A, Pallardó LM. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med 2015;4:1866-89. [PMID: 26512703 DOI: 10.3390/jcm4101866] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
362 Wharton S. Current Perspectives on Long-term Obesity Pharmacotherapy. Can J Diabetes 2016;40:184-91. [PMID: 26507402 DOI: 10.1016/j.jcjd.2015.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
363 Dar S, Tahrani AA, Piya MK. The role of GLP-1 receptor agonists as weight loss agents in patients with and without type 2 diabetes: The role of GLP-1 receptor agonists as weight loss agents. Pract Diab 2015;32:297-300b. [DOI: 10.1002/pdi.1978] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
364 Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabbà C, Guastamacchia E, Triggiani V. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology 2015;3:1094-103. [DOI: 10.1111/andr.12099] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
365 Heni M, Kullmann S, Gallwitz B, Häring HU, Preissl H, Fritsche A. Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans. Mol Metab 2015;4:971-6. [PMID: 26909313 DOI: 10.1016/j.molmet.2015.09.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
366 Halpern B, Mancini MC, Halpern A. Brown adipose tissue: what have we learned since its recent identification in human adults. Arq Bras Endocrinol Metabol 2014;58:889-99. [PMID: 25627043 DOI: 10.1590/0004-2730000003492] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
367 ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Deacon CF, Holst JJ, Konrad RJ, Sloan JH, Drent ML, Diamant M, IJzerman RG. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia 2015;58:2688-98. [PMID: 26385462 DOI: 10.1007/s00125-015-3754-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 8.7] [Reference Citation Analysis]
368 Roth CL. Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity Intervention. J Clin Med 2015;4:1774-97. [PMID: 26371051 DOI: 10.3390/jcm4091774] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
369 Gautier JF, Martinez L, Penfornis A, Eschwège E, Charpentier G, Huret B, Madani S, Gourdy P. Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study. Adv Ther 2015;32:838-53. [PMID: 26424330 DOI: 10.1007/s12325-015-0245-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
370 van Bloemendaal L, Veltman DJ, ten Kulve JS, Drent ML, Barkhof F, Diamant M, IJzerman RG. Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation. Obesity (Silver Spring). 2015;23:2075-2082. [PMID: 26331843 DOI: 10.1002/oby.21200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
371 Camilleri M, Acosta A. Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. Gastrointest Endosc 2016;83:48-56. [PMID: 26271184 DOI: 10.1016/j.gie.2015.08.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
372 Morano S, Romagnoli E, Filardi T, Nieddu L, Mandosi E, Fallarino M, Turinese I, Dagostino MP, Lenzi A, Carnevale V. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Acta Diabetol 2015;52:727-32. [PMID: 25577244 DOI: 10.1007/s00592-014-0710-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
373 Turer CB. Tools for Successful Weight Management in Primary Care. Am J Med Sci 2015;350:485-97. [PMID: 26218666 DOI: 10.1097/MAJ.0000000000000530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
374 van Bloemendaal L, Veltman DJ, Ten Kulve JS, Groot PF, Ruhé HG, Barkhof F, Sloan JH, Diamant M, Ijzerman RG. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. Diabetes Obes Metab. 2015;17:878-886. [PMID: 26094857 DOI: 10.1111/dom.12506] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 9.6] [Reference Citation Analysis]
375 Palikhe G, Gupta R, Behera BN, Sachdeva N, Gangadhar P, Bhansali A. Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus. Obes Surg 2014;24:529-35. [PMID: 24272885 DOI: 10.1007/s11695-013-1114-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
376 Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. [PMID: 26213556 DOI: 10.7573/dic.212283] [Cited by in Crossref: 197] [Cited by in F6Publishing: 212] [Article Influence: 28.1] [Reference Citation Analysis]
377 Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17:1021-1032. [PMID: 26040215 DOI: 10.1111/dom.12502] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
378 Finan B, Clemmensen C, Müller TD. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 2015;418 Pt 1:42-54. [PMID: 26151488 DOI: 10.1016/j.mce.2015.07.003] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 8.7] [Reference Citation Analysis]
379 Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab 2015;6:109-34. [PMID: 26137215 DOI: 10.1177/2042018815580257] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
380 Alvarez CA, Lingvay I, Vuylsteke V, Koffarnus RL, McGuire DK. Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. Clin Pharmacol Ther 2015;98:145-61. [PMID: 25963811 DOI: 10.1002/cpt.143] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
381 Oh S, Chon S, Ahn KJ, Jeong IK, Kim BJ, Kang JG. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea. Diabetes Metab J 2015;39:177-87. [PMID: 26124987 DOI: 10.4093/dmj.2015.39.3.177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
382 Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLoS One 2015;10:e0126769. [PMID: 26121478 DOI: 10.1371/journal.pone.0126769] [Cited by in Crossref: 107] [Cited by in F6Publishing: 115] [Article Influence: 15.3] [Reference Citation Analysis]
383 Candeias EM, Sebastião IC, Cardoso SM, Correia SC, Carvalho CI, Plácido AI, Santos MS, Oliveira CR, Moreira PI, Duarte AI. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J Diabetes 2015; 6(6): 807-827 [PMID: 26131323 DOI: 10.4239/wjd.v6.i6.807] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
384 González N, Moreno P, Jensen RT. Bombesin receptor subtype 3 as a potential target for obesity and diabetes. Expert Opin Ther Targets 2015;19:1153-70. [PMID: 26066663 DOI: 10.1517/14728222.2015.1056154] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
385 Sørensen G, Reddy IA, Weikop P, Graham DL, Stanwood GD, Wortwein G, Galli A, Fink-Jensen A. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol Behav 2015;149:262-8. [PMID: 26072178 DOI: 10.1016/j.physbeh.2015.06.013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 10.7] [Reference Citation Analysis]
386 Vahle JL, Byrd RA, Blackbourne JL, Martin JA, Sorden SD, Ryan T, Pienkowski T, Rosol TJ, Snyder PW, Klöppel G. Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys. Toxicol Pathol 2015;43:1004-14. [PMID: 26059826 DOI: 10.1177/0192623315588999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
387 Liu J, Wu MH, Gao Y. Molecular mechanisms of incretin hormone secretion. Shijie Huaren Xiaohua Zazhi 2015; 23(16): 2582-2587 [DOI: 10.11569/wcjd.v23.i16.2582] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
388 Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015;95:513-548. [PMID: 25834231 DOI: 10.1152/physrev.00013.2014] [Cited by in Crossref: 239] [Cited by in F6Publishing: 255] [Article Influence: 34.1] [Reference Citation Analysis]
389 Fulcher G, Roberts A, Sinha A, Proietto J. What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. Diabetes Research and Clinical Practice 2015;108:405-13. [DOI: 10.1016/j.diabres.2015.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
390 Scheen A, Esser N, Paquot N. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes & Metabolism 2015;41:183-94. [DOI: 10.1016/j.diabet.2015.02.003] [Cited by in Crossref: 96] [Cited by in F6Publishing: 104] [Article Influence: 13.7] [Reference Citation Analysis]
391 de Mello AH, Prá M, Cardoso LC, de Bona Schraiber R, Rezin GT. Incretin-based therapies for obesity treatment. Metabolism 2015;64:967-81. [PMID: 26072135 DOI: 10.1016/j.metabol.2015.05.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
392 Jensterle M, Pirš B, Goričar K, Dolžan V, Janež A. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol 2015;71:817-24. [PMID: 25991051 DOI: 10.1007/s00228-015-1868-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
393 Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015;23:1119-1129. [PMID: 25959380 DOI: 10.1002/oby.21107] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
394 Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Heerspink HJL, van Raalte DH. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. The Lancet Diabetes & Endocrinology 2015;3:367-81. [DOI: 10.1016/s2213-8587(15)00030-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 8.9] [Reference Citation Analysis]
395 Zhang X, Liu Y, Xiong D, Xie C. Insulin combined with Chinese medicine improves glycemic outcome through multiple pathways in patients with type 2 diabetes mellitus. J Diabetes Investig 2015;6:708-15. [PMID: 26543546 DOI: 10.1111/jdi.12352] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
396 Gamble JM, Clarke A, Myers KJ, Agnew MD, Hatch K, Snow MM, Davis EM. Incretin-based medications for type 2 diabetes: an overview of reviews. Diabetes Obes Metab 2015;17:649-58. [PMID: 25772666 DOI: 10.1111/dom.12465] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
397 García-Prieto CF, Gil-Ortega M, Aránguez I, Ortiz-Besoain M, Somoza B, Fernández-Alfonso MS. Vascular AMPK as an attractive target in the treatment of vascular complications of obesity. Vascul Pharmacol 2015;67-69:10-20. [PMID: 25869500 DOI: 10.1016/j.vph.2015.02.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
398 Chiefari E, Capula C, Vero A, Oliverio R, Puccio L, Liguori R, Pullano V, Greco M, Foti D, Tirinato D, Vero R, Brunetti A. Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy. Diabetes Technol Ther 2015;17:468-74. [PMID: 25844858 DOI: 10.1089/dia.2014.0412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
399 Jinnouchi H, Sugiyama S, Yoshida A, Hieshima K, Kurinami N, Suzuki T, Miyamoto F, Kajiwara K, Matsui K, Jinnouchi T. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res 2015;2015:706416. [PMID: 25922845 DOI: 10.1155/2015/706416] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
400 Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014;15:181-7. [PMID: 24811133 DOI: 10.1007/s11154-014-9289-5] [Cited by in Crossref: 114] [Cited by in F6Publishing: 121] [Article Influence: 16.3] [Reference Citation Analysis]
401 Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15:197-207. [PMID: 24791975 DOI: 10.1007/s11154-014-9287-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
402 Inoue Y, Nakamura A, Kondo Y, Hamano K, Satoh S, Terauchi Y. A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes. J Clin Pharmacol 2015;55:831-8. [PMID: 25677642 DOI: 10.1002/jcph.483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
403 Hayes RP, Delozier AM. Reliability, Validity, and Responsiveness of the Impact of Weight on Self-Perceptions Questionnaire (IW-SP) in Individuals with Type 2 Diabetes and Obesity. Diabetes Technology & Therapeutics 2015;17:210-4. [DOI: 10.1089/dia.2014.0142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
404 Buysschaert M, Amoussou-guenou D, Yanogo D, Djrolo F. Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015. Médecine des Maladies Métaboliques 2015;9:158-163. [DOI: 10.1016/s1957-2557(15)30036-5] [Reference Citation Analysis]
405 Seeley RJ, Chambers AP, Sandoval DA. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab 2015;21:369-78. [PMID: 25662404 DOI: 10.1016/j.cmet.2015.01.001] [Cited by in Crossref: 157] [Cited by in F6Publishing: 131] [Article Influence: 22.4] [Reference Citation Analysis]
406 Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol 2015;14:10. [PMID: 25616979 DOI: 10.1186/s12933-015-0178-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
407 Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res. 2015;2015:157201. [PMID: 25688373 DOI: 10.1155/2015/157201] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
408 Khan M, Ouyang J, Perkins K, Nair S, Joseph F. Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus. J Diabetes Res 2015;2015:162718. [PMID: 25688374 DOI: 10.1155/2015/162718] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
409 Lipowsky C, Sze L, Krull I, Brändle M. Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in Switzerland. Diabetes Ther 2015;6:41-7. [PMID: 25576400 DOI: 10.1007/s13300-014-0093-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
410 Vest AR, Young JB. 49 Cardiovascular Disease in the Bariatric Surgery Patient. Minimally Invasive Bariatric Surgery 2015. [DOI: 10.1007/978-1-4939-1637-5_49] [Reference Citation Analysis]
411 Ionut V, Bergman RN. The Disease of Obesity. The Clinician’s Guide to the Treatment of Obesity 2015. [DOI: 10.1007/978-1-4939-2146-1_1] [Reference Citation Analysis]
412 Ahima RS. Overview of Metabolic Syndrome. Metabolic Syndrome 2015. [DOI: 10.1007/978-3-319-12125-3_1-1] [Reference Citation Analysis]
413 Burguera B, Tur J. 3 Medical Management of Obesity. Minimally Invasive Bariatric Surgery 2015. [DOI: 10.1007/978-1-4939-1637-5_3] [Reference Citation Analysis]
414 Preiato VL, Serban ED, Pasquali R, Pagotto U. Prescription Medications for the Treatment of Obesity. Multidisciplinary Approach to Obesity 2015. [DOI: 10.1007/978-3-319-09045-0_23] [Reference Citation Analysis]
415 Gluud LL, Knop FK, Vilsbøll T. Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open. 2014;4:e005325. [PMID: 25526792 DOI: 10.1136/bmjopen-2014-005325] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
416 Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 2014;37:1499-508. [PMID: 24855154 DOI: 10.2337/dc13-2743] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 11.9] [Reference Citation Analysis]
417 Junker AE, Gluud LL, Pedersen J, Langhoff JL, Holst JJ, Knop FK, Vilsbøll T. A 25-year-old woman with type 2 diabetes and liver disease. Case Rep Gastroenterol 2014;8:398-403. [PMID: 25606030 DOI: 10.1159/000369968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
418 Dharmalingam M. Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective. Ther Adv Endocrinol Metab 2014;5:159-65. [PMID: 25489471 DOI: 10.1177/2042018814552657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
419 D'Alessio D, Häring HU, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain MP, Vincent M, Pilorget V, Yki-Järvinen H; EAGLE Investigators. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab 2015;17:170-8. [PMID: 25359159 DOI: 10.1111/dom.12406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
420 Ariel D, Kim S, Abbasi F, Lamendola C, Liu A, Reaven G. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism and Cardiovascular Diseases 2014;24:1317-22. [DOI: 10.1016/j.numecd.2014.06.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
421 Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. The Lancet 2014;384:2228-34. [DOI: 10.1016/s0140-6736(14)61335-0] [Cited by in Crossref: 276] [Cited by in F6Publishing: 291] [Article Influence: 34.5] [Reference Citation Analysis]
422 Scholz GH, Fleischmann H. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Ther Adv Endocrinol Metab 2014;5:95-123. [PMID: 25419451 DOI: 10.1177/2042018814556099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
423 Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol 2015;31:142-52. [PMID: 25661549 DOI: 10.1016/j.cjca.2014.11.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
424 Chalmer T, Almdal TP, Vilsbøll T, Knop FK. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf 2015;14:171-80. [PMID: 25363438 DOI: 10.1517/14740338.2015.975205] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
425 Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. The Lancet Diabetes & Endocrinology 2014;2:911-22. [DOI: 10.1016/s2213-8587(14)70004-x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 132] [Article Influence: 15.1] [Reference Citation Analysis]
426 Wang XC, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol 2014; 20(40): 14821-14830 [PMID: 25356042 DOI: 10.3748/wjg.v20.i40.14821] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 61] [Article Influence: 6.9] [Reference Citation Analysis]
427 Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, Wakabayashi G. Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol (Lausanne). 2014;5:164. [PMID: 25386164 DOI: 10.3389/fendo.2014.00164] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 8.9] [Reference Citation Analysis]
428 Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord 2014;15:329-41. [DOI: 10.1007/s11154-014-9298-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
429 Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res. 2014;Epub ahead of print. [PMID: 25330463 DOI: 10.3109/07435800.2014.966385] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
430 Fournier M, Germe M, Theobald K, Scholz GH, Lehmacher W. Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus. Ger Med Sci. 2014;12:Doc14. [PMID: 25332702 DOI: 10.3205/000199] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
431 Imai K, Tsujimoto T, Goto A, Goto M, Kishimoto M, Yamamoto-Honda R, Noto H, Kajio H, Noda M. Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes. Diabetol Metab Syndr 2014;6:110. [PMID: 25349635 DOI: 10.1186/1758-5996-6-110] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
432 Azim S, Baker WL, White WB. Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus. Curr Cardiol Rep 2014;16. [DOI: 10.1007/s11886-014-0541-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
433 Yehuda AB, Zinger A, Durso S. The older patient with diabetes: a practical approach. Diabetes Metab Res Rev. 2014;30:88-95. [PMID: 24123811 DOI: 10.1002/dmrr.2485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
434 Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between metabolic syndrome and meal-induced glucagon like peptide-1 response in type 1 diabetic patients在1型糖尿病患者中代谢综合征与进餐诱导的胰高血糖素样肽-1应答之间的关系: Metabolic syndrome and GLP-1 in T1DM. Journal of Diabetes 2015;7:340-6. [DOI: 10.1111/1753-0407.12194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
435 Hansen HH, Hansen G, Paulsen S, Vrang N, Mark M, Jelsing J, Klein T. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat. European Journal of Pharmacology 2014;741:254-63. [DOI: 10.1016/j.ejphar.2014.08.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
436 Rotella CM, Cresci B. Cosa c’è all’orizzonte della farmacologia dell’obesità. L'Endocrinologo 2014;15:207-212. [DOI: 10.1007/s40619-014-0064-3] [Reference Citation Analysis]
437 Bi Y, Zhang B, Xu W, Yang H, Feng W, Li C, Tong G, Li M, Wang X, Shen S, Zhu B, Weng J, Zhu D. Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes. Acta Diabetol 2014;51:865-73. [PMID: 25118999 DOI: 10.1007/s00592-014-0638-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
438 Smilowitz NR, Donnino R, Schwartzbard A. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. Circulation. 2014;129:2305-2312. [PMID: 24891623 DOI: 10.1161/circulationaha.113.006985] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
439 Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Expert Opin Pharmacother 2014;15:2487-500. [PMID: 25260877 DOI: 10.1517/14656566.2014.965678] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
440 Liu J, Wang G, Jia Y, Xu Y. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease: GLP-1 Receptor Agonists and NAFLD. Diabetes Metab Res Rev 2015;31:329-35. [DOI: 10.1002/dmrr.2580] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
441 Kiadaliri AA, Gerdtham UG, Eliasson B, Carlsson KS. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. Diabetes Ther 2014;5:591-607. [PMID: 25213800 DOI: 10.1007/s13300-014-0080-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
442 Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L, Tong N. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials-1/:meta. J Diabetes. 2015;7:329-339. [PMID: 25043423 DOI: 10.1111/1753-0407.12198] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
443 Mcgovern AP, Munro N, Watters K, Feher M. Profound weight reduction with GLP-1 agonist therapy: a delayed hyper-response. Pract Diab 2014;31:286-286a. [DOI: 10.1002/pdi.1887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
444 Schwartz S. Evidence-based practice use of incretin-based therapy in the natural history of diabetes. Postgrad Med 2014;126:66-84. [PMID: 24918793 DOI: 10.3810/pgm.2014.05.2757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
445 Yabe D, Seino Y. Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 2014;9:659-70. [DOI: 10.1586/17446651.2014.949672] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
446 Keen S, Craven K, Kolasa KM. Nutrition Strategies for Patients on New Incretin Therapies for Type 2 Diabetes. Nutrition Today 2014;49:254-261. [DOI: 10.1097/nt.0000000000000044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
447 Russo GT, Labate AM, Giandalia A, Romeo EL, Villari P, Alibrandi A, Perdichizzi G, Cucinotta D. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest 2015;38:81-9. [PMID: 25173876 DOI: 10.1007/s40618-014-0163-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
448 Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne) 2014;5:140. [PMID: 25221543 DOI: 10.3389/fendo.2014.00140] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
449 Muscogiuri G, Cignarelli A, Giorgino F, Prodam F, Santi D, Tirabassi G, Balercia G, Modica R, Faggiano A, Colao A. GLP-1: benefits beyond pancreas. J Endocrinol Invest 2014;37:1143-53. [PMID: 25107343 DOI: 10.1007/s40618-014-0137-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
450 Wang T, Gou Z, Wang F, Ma M, Zhai SD. Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS One 2014;9:e103798. [PMID: 25089625 DOI: 10.1371/journal.pone.0103798] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
451 Voukali M, Kastrinelli I, Stragalinou S, Tasiopoulou D, Paraskevopoulou P, Katsilambros N, Kokkinos A, Tentolouris N, Ioannidis I. Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide. J Diabetes Res. 2014;2014:304032. [PMID: 25165723 DOI: 10.1155/2014/304032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
452 Stranges P, Khanderia U. Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf 2012;3:185-201. [PMID: 25083236 DOI: 10.1177/2042098612454290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
453 Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48:107-115. [PMID: 25074632 DOI: 10.1007/s12020-014-0361-4] [Cited by in Crossref: 115] [Cited by in F6Publishing: 100] [Article Influence: 14.4] [Reference Citation Analysis]
454 Ottney A. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. Am J Health Syst Pharm. 2013;70:2097-2103. [PMID: 24249759 DOI: 10.2146/ajhp130081] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
455 Anholm C, Kumarathurai P, Klit MS, Kristiansen OP, Nielsen OW, Ladelund S, Madsbad S, Sajadieh A, Haugaard SB; AddHope2 Trial Study Group. Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. BMJ Open 2014;4:e005942. [PMID: 25031198 DOI: 10.1136/bmjopen-2014-005942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
456 Merlino DJ, Blomain ES, Aing AS, Waldman SA. Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy. J Clin Med 2014;3:763-94. [PMID: 26237477 DOI: 10.3390/jcm3030763] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
457 Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114:1788-803. [PMID: 24855202 DOI: 10.1161/CIRCRESAHA.114.301958] [Cited by in Crossref: 253] [Cited by in F6Publishing: 264] [Article Influence: 31.6] [Reference Citation Analysis]
458 Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20(26): 8377-8392 [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
459 Lin D, Wang Q, Ran H, Liu K, Wang Y, Wang J, Liu Y, Chen R, Sun Y, Liu R, Ding F. Abnormal Response to the Anorexic Effect of GHS-R Inhibitors and Exenatide in Male Snord116 Deletion Mouse Model for Prader-Willi Syndrome. Endocrinology 2014;155:2355-62. [DOI: 10.1210/en.2013-2083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
460 Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2013;28:262-274. [PMID: 24396690 DOI: 10.3803/enm.2013.28.4.262] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
461 Sauer N, Rösch T, Pezold J, Reining F, Anders M, Groth S, Schachschal G, Mann O, Aberle J. A new endoscopically implantable device (SatiSphere) for treatment of obesity--efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg. 2013;23:1727-1733. [PMID: 23780702 DOI: 10.1007/s11695-013-1005-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
462 Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014;5:135-48. [PMID: 24790728 DOI: 10.1177/2040622314522848] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 8.5] [Reference Citation Analysis]
463 Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30. [PMID: 24843641 DOI: 10.1111/jdi.12065] [Cited by in Crossref: 175] [Cited by in F6Publishing: 181] [Article Influence: 21.9] [Reference Citation Analysis]
464 McCarty MF, DiNicolantonio JJ. The cardiometabolic benefits of glycine: Is glycine an 'antidote' to dietary fructose? Open Heart 2014;1:e000103. [PMID: 25332814 DOI: 10.1136/openhrt-2014-000103] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
465 Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO; ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014;171:P1-29. [PMID: 24849517 DOI: 10.1530/EJE-14-0253] [Cited by in Crossref: 331] [Cited by in F6Publishing: 365] [Article Influence: 41.4] [Reference Citation Analysis]
466 Jorsal A, Wiggers H, Holmager P, Nilsson B, Nielsen R, Boesgaard TW, Kumme A, Møller JE, Videbæk L, Kistorp C, Gustafsson I, Tarnow L, Flyvbjerg A. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study). BMJ Open 2014;4:e004885. [PMID: 24844271 DOI: 10.1136/bmjopen-2014-004885] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
467 Kim J, Samson SL. Cardiovascular effects of incretin therapy in diabetes care. Metab Syndr Relat Disord 2014;12:303-10. [PMID: 24842063 DOI: 10.1089/met.2014.0035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
468 Ma J, Lin TC, Liu W. Gastrointestinal hormones and polycystic ovary syndrome. Endocrine 2014;47:668-78. [PMID: 24791734 DOI: 10.1007/s12020-014-0275-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
469 Plourde CÉ, Grenier-Larouche T, Caron-Dorval D, Biron S, Marceau S, Lebel S, Biertho L, Tchernof A, Richard D, Carpentier AC. Biliopancreatic diversion with duodenal switch improves insulin sensitivity and secretion through caloric restriction. Obesity (Silver Spring) 2014;22:1838-46. [PMID: 24760439 DOI: 10.1002/oby.20771] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
470 Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366. [PMID: 24736555 DOI: 10.1136/bmj.g2366] [Cited by in Crossref: 145] [Cited by in F6Publishing: 160] [Article Influence: 18.1] [Reference Citation Analysis]
471 Vora J. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S226-S232. [PMID: 23882050 DOI: 10.2337/dcs13-2036] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
472 Knop FK, Taylor R. Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction. Diabetes Care. 2013;36 Suppl 2:S287-S291. [PMID: 23882061 DOI: 10.2337/dcs13-2032] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
473 Gallwitz B, Bretzel RG. How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. Diabetes Care 2013;36 Suppl 2:S180-9. [PMID: 23882044 DOI: 10.2337/dcS13-2012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
474 Gorgojo-martínez J. Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad. Hipertensión y Riesgo Vascular 2014;31:45-57. [DOI: 10.1016/j.hipert.2014.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
475 Stears A, Hames C. Diagnosis and management of lipodystrophy: a practical update. Clinical Lipidology 2014;9:235-59. [DOI: 10.2217/clp.14.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
476 Ahmadieh H, Azar ST. The role of incretin-based therapies in prediabetes: a review. Prim Care Diabetes. 2014;8:286-294. [PMID: 24666932 DOI: 10.1016/j.pcd.2014.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
477 Umpierrez GE, Meneghini L. Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. Endocr Pract. 2013;19:718-728. [PMID: 23512382 DOI: 10.4158/ep12292.ra] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
478 van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221:T1-16. [PMID: 24323912 DOI: 10.1530/joe-13-0414] [Cited by in Crossref: 142] [Cited by in F6Publishing: 148] [Article Influence: 17.8] [Reference Citation Analysis]
479 Gallwitz B. Extra-pancreatic effects of incretin-based therapies. Endocrine 2014;47:360-71. [PMID: 24604239 DOI: 10.1007/s12020-014-0223-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
480 Calbet JA, Ponce-González JG, Pérez-Suárez I, de la Calle Herrero J, Holmberg HC. A time-efficient reduction of fat mass in 4 days with exercise and caloric restriction. Scand J Med Sci Sports 2015;25:223-33. [PMID: 24602091 DOI: 10.1111/sms.12194] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
481 Punjabi M, Arnold M, Rüttimann E, Graber M, Geary N, Pacheco-López G, Langhans W. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Endocrinology 2014;155:1690-9. [PMID: 24601880 DOI: 10.1210/en.2013-1447] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
482 Brandl EJ, Tiwari AK, Chowdhury NI, Zai CC, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics 2014;15:423-31. [DOI: 10.2217/pgs.13.247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
483 Elkhenini H, New JP, Summers LK, Syed AA. Liraglutide therapy in obese people with type 2 diabetes — Experience of a weight management centre. European Journal of Internal Medicine 2014;25:e38-9. [DOI: 10.1016/j.ejim.2013.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
484 Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014;68:682-91. [PMID: 24548654 DOI: 10.1111/ijcp.12384] [Cited by in Crossref: 142] [Cited by in F6Publishing: 148] [Article Influence: 17.8] [Reference Citation Analysis]
485 Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H; Tofogliflozin 004 and 005 Study group. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 2014;15:749-66. [PMID: 24512053 DOI: 10.1517/14656566.2014.887680] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 7.6] [Reference Citation Analysis]
486 Lotfy M, Singh J, Rashed H, Tariq S, Zilahi E, Adeghate E. Mechanism of the beneficial and protective effects of exenatide in diabetic rats. J Endocrinol 2014;220:291-304. [PMID: 24353307 DOI: 10.1530/JOE-13-0426] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
487 Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170:451-459. [PMID: 24362411 DOI: 10.1530/eje-13-0797] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 10.9] [Reference Citation Analysis]
488 Corey KE, Kaplan LM. Obesity and Liver Disease. Clinics in Liver Disease 2014;18:1-18. [DOI: 10.1016/j.cld.2013.09.019] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 10.6] [Reference Citation Analysis]
489 Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH, Beglinger C. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 2014;9:e87488. [PMID: 24489924 DOI: 10.1371/journal.pone.0087488] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 8.4] [Reference Citation Analysis]
490 Díaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res Clin Pract 2014;104:92-6. [PMID: 24530118 DOI: 10.1016/j.diabres.2014.01.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
491 Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28:399-405. [PMID: 24561125 DOI: 10.1016/j.jdiacomp.2014.01.009] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
492 Skov J, Frystyk J, Christiansen JS. GLP-1 infusion reduces IGFBP-1 serum level in humans. Growth Horm IGF Res 2014;24:67-70. [PMID: 24477242 DOI: 10.1016/j.ghir.2014.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
493 Kishimoto M, Noda M. Effects of exenatide in a morbidly obese patient with type 2 diabetes. Diabetes Ther 2014;5:323-32. [PMID: 24442463 DOI: 10.1007/s13300-014-0050-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
494 Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 2014;16:673-688. [PMID: 24373150 DOI: 10.1111/dom.12251] [Cited by in Crossref: 71] [Cited by in F6Publishing: 78] [Article Influence: 8.9] [Reference Citation Analysis]
495 Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 2014;103:269-75. [PMID: 24485345 DOI: 10.1016/j.diabres.2014.01.010] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
496 Bray GA. Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring). 2013;21:893-899. [PMID: 23520198 DOI: 10.1002/oby.20394] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
497 Kelly AS. The role of glucagon-like peptide-1 receptor agonists for the treatment of adolescent obesity. Expert Rev Endocrinol Metab 2013;8:315-7. [PMID: 30736144 DOI: 10.1586/17446651.2013.811913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
498 Ishøy PL, Knop FK, Broberg BV, Baandrup L, Fagerlund B, Jørgensen NR, Andersen UB, Rostrup E, Glenthøj BY, Ebdrup BH. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open 2014;4:e004158. [PMID: 24401727 DOI: 10.1136/bmjopen-2013-004158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
499 Vetter ML, Amaro A, Volger S. Nutritional management of type 2 diabetes mellitus and obesity and pharmacologic therapies to facilitate weight loss. Postgrad Med 2014;126:139-52. [PMID: 24393761 DOI: 10.3810/pgm.2014.01.2734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
500 Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, Rajagopalan S. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014;27:130-9. [PMID: 24263424 DOI: 10.1093/ajh/hpt196] [Cited by in Crossref: 86] [Cited by in F6Publishing: 93] [Article Influence: 10.8] [Reference Citation Analysis]
501 Derosa G, Maffioli P. Pharmacotherapy for Obesity. Integrative Weight Management 2014. [DOI: 10.1007/978-1-4939-0548-5_18] [Reference Citation Analysis]
502 Ueno H, Nakazato M. The Prospects of Novel Anti-obesity Drugs. J Jpn Soc Intern Med 2014;103:753-759. [DOI: 10.2169/naika.103.753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
503 Vakilgilani T, Zac-varghese S, Bloom SR. Gut Peptides. Treatment of the Obese Patient 2014. [DOI: 10.1007/978-1-4939-2311-3_3] [Reference Citation Analysis]
504 Bandeira F, Moura F, Costi BB. GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes. Endocrinology and Diabetes 2014. [DOI: 10.1007/978-1-4614-8684-8_30] [Reference Citation Analysis]
505 Vakilgilani T, Zac-varghese S, Bloom SR. Gut Peptides. Treatment of the Obese Patient 2014. [DOI: 10.1007/978-1-4939-1203-2_3] [Reference Citation Analysis]
506 Park SH. Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Korean J Med 2014;86:425. [DOI: 10.3904/kjm.2014.86.4.425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
507 Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014;10:88-103. [PMID: 24375052 DOI: 10.1038/nrneph.2013.272] [Cited by in Crossref: 131] [Cited by in F6Publishing: 137] [Article Influence: 14.6] [Reference Citation Analysis]
508 Scott R, Tan T, Bloom S. Gut hormones and obesity: physiology and therapies. Vitam Horm 2013;91:143-94. [PMID: 23374716 DOI: 10.1016/B978-0-12-407766-9.00007-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
509 Pappachan JM, Antonio FA, Edavalath M, Mukherjee A. Non-alcoholic fatty liver disease: a diabetologist's perspective. Endocrine 2014;45:344-53. [PMID: 24287794 DOI: 10.1007/s12020-013-0087-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
510 Cohen ND, Audehm R, Pretorius E, Kaye J, Chapman LH, Colagiuri S. The rationale for combining GLP-1 receptor agonists with basal insulin. Med J Aust 2013;199:246-9. [PMID: 23984780 DOI: 10.5694/mja12.11856] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
511 Miras AD, le Roux CW. Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int J Obes (Lond) 2014;38:325-33. [PMID: 24213310 DOI: 10.1038/ijo.2013.205] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
512 Reddy IA, Stanwood GD, Galli A. Moving beyond energy homeostasis: new roles for glucagon-like peptide-1 in food and drug reward. Neurochem Int 2014;73:49-55. [PMID: 24140429 DOI: 10.1016/j.neuint.2013.10.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
513 Krentz AJ, Hompesch M. Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift? Drugs 2013;73:1649-51. [DOI: 10.1007/s40265-013-0123-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
514 Forst T, Pfützner A. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2013;14:2281-96. [DOI: 10.1517/14656566.2013.838559] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
515 Singh A, Donnino R, Weintraub H, Schwartzbard A. Effect of strict glycemic control in patients with diabetes mellitus on frequency of macrovascular events. Am J Cardiol 2013;112:1033-8. [PMID: 23768455 DOI: 10.1016/j.amjcard.2013.05.044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
516 George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014;19:65-76. [PMID: 24064009 DOI: 10.1177/1074248413501017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
517 Davidson JA. Incretin-based therapies: focus on effects beyond glycemic control alone. Diabetes Ther 2013;4:221-38. [PMID: 24057947 DOI: 10.1007/s13300-013-0040-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
518 Kenkre J, Tan T, Bloom S. Treating the obese diabetic. Expert Rev Clin Pharmacol 2013;6:171-83. [PMID: 23473594 DOI: 10.1586/ecp.13.5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
519 Ziauddeen H, Fletcher PC. Central nervous system biomarkers for antiobesity drug development. Drug Discov Today 2013;18:1282-91. [PMID: 23993917 DOI: 10.1016/j.drudis.2013.08.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
520 Mathers MC, Zarbock SD, Sutton EE. New and Future Medications for the Treatment of Type 2 Diabetes Mellitus. American Journal of Lifestyle Medicine 2014;8:260-80. [DOI: 10.1177/1559827613498694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
521 Li P, Tiwari HK, Lin WY, Allison DB, Chung WK, Leibel RL, Yi N, Liu N. Genetic association analysis of 30 genes related to obesity in a European American population. Int J Obes (Lond) 2014;38:724-9. [PMID: 23900445 DOI: 10.1038/ijo.2013.140] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
522 Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38-47. [PMID: 23829656 DOI: 10.1111/dom.12175] [Cited by in Crossref: 121] [Cited by in F6Publishing: 134] [Article Influence: 13.4] [Reference Citation Analysis]
523 Morelli M, Gaggini M, Daniele G, Marraccini P, Sicari R, Gastaldelli A. Ectopic fat: the true culprit linking obesity and cardiovascular disease? Thromb Haemost 2013;110:651-60. [PMID: 23884194 DOI: 10.1160/TH13-04-0285] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
524 Maljaars J. Overeating makes the gut grow fonder; new insights in gastrointestinal satiety signaling in obesity. Curr Opin Gastroenterol 2013;29:177-83. [PMID: 23295637 DOI: 10.1097/MOG.0b013e32835d9fe0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
525 Kim SH, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, Grove K, Tomasso V, Ochoa H, Liu YV. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36:3276-3282. [PMID: 23835684 DOI: 10.2337/dc13-0354] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 6.6] [Reference Citation Analysis]
526 Bloomgarden ZT, Blonde L, Garber AJ, Wysham CH. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. Endocr Pract 2012;18 Suppl 3:6-26; quiz 27-8. [PMID: 23315305 DOI: 10.4158/EP12300.RA] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
527 Ellenbroek JH, Töns HAM, Westerouen van Meeteren MJA, de Graaf N, Hanegraaf MA, Rabelink TJ, Carlotti F, de Koning EJP. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia 2013;56:1980-6. [DOI: 10.1007/s00125-013-2957-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
528 Cignarelli A, Giorgino F, Vettor R. Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. Arch Physiol Biochem. 2013;119:139-150. [PMID: 23724947 DOI: 10.3109/13813455.2013.796996] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
529 Esposito K, Gentile S, Candido R, De Micheli A, Gallo M, Medea G, Ceriello A; Associazione Medici Diabetologi. Management of hyperglycemia in type 2 diabetes: evidence and uncertainty. Cardiovasc Diabetol 2013;12:81. [PMID: 23721170 DOI: 10.1186/1475-2840-12-81] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
530 Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 2014;16:9-21. [DOI: 10.1111/dom.12119] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 9.8] [Reference Citation Analysis]
531 Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 2013;23:4011-8. [PMID: 23743288 DOI: 10.1016/j.bmcl.2013.05.022] [Cited by in Crossref: 103] [Cited by in F6Publishing: 86] [Article Influence: 11.4] [Reference Citation Analysis]
532 Kondo Y, Satoh S, Nagakura J, Kimura M, Nezu U, Terauchi Y. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig 2013;4:571-5. [PMID: 24843711 DOI: 10.1111/jdi.12082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
533 Simsek S, de Galan BE. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes. Curr Opin Lipidol. 2012;23:540-547. [PMID: 23160401 DOI: 10.1097/mol.0b013e3283590b8f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
534 Zoicas F, Droste M, Mayr B, Buchfelder M, Schöfl C. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol 2013;168:699-706. [PMID: 23392214 DOI: 10.1530/EJE-12-0997] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 7.8] [Reference Citation Analysis]
535 Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris) 2013;74:515-22. [PMID: 23570814 DOI: 10.1016/j.ando.2012.06.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
536 Rizzo M, Nikolic D, Banach M, Giglio RV, Patti AM, Di Bartolo V, Tamburello A, Zabbara A, Pecoraro G, Montalto G, Rizvi AA. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective. Clinical Lipidology 2013;8:173-81. [DOI: 10.2217/clp.13.8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
537 Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567-575. [PMID: 23542788 DOI: 10.1038/nm.3128] [Cited by in Crossref: 332] [Cited by in F6Publishing: 349] [Article Influence: 36.9] [Reference Citation Analysis]
538 Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013;36:2543-2550. [PMID: 23536584 DOI: 10.2337/dc12-2006] [Cited by in Crossref: 121] [Cited by in F6Publishing: 128] [Article Influence: 13.4] [Reference Citation Analysis]
539 Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15:737-749. [PMID: 23433305 DOI: 10.1111/dom.12085] [Cited by in Crossref: 135] [Cited by in F6Publishing: 143] [Article Influence: 15.0] [Reference Citation Analysis]
540 Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol. 2013;9:425-433. [PMID: 23478327 DOI: 10.1038/nrendo.2013.47] [Cited by in Crossref: 143] [Cited by in F6Publishing: 144] [Article Influence: 15.9] [Reference Citation Analysis]
541 Skov J, Dejgaard A, Frøkiær J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013;98:E664-71. [PMID: 23463656 DOI: 10.1210/jc.2012-3855] [Cited by in Crossref: 121] [Cited by in F6Publishing: 129] [Article Influence: 13.4] [Reference Citation Analysis]
542 Nadal Llover M, Pellicer Jacomet MÀ. Aportaciones de los nuevos fármacos para la diabetes. FMC - Formación Médica Continuada en Atención Primaria 2013;20:155-165. [DOI: 10.1016/s1134-2072(13)70543-7] [Reference Citation Analysis]
543 Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 2013;30:81-101. [PMID: 23423907 DOI: 10.1007/s12325-013-0009-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
544 Krempf M, Hochberg G, Eschwège E, Danchin N, Grignon C, Bekka S. Diabète de type 2 et stratégies thérapeutiques : quelles pratiques aujourd’hui en France ? Résultats de l’enquête EVOLUTIV. Médecine des Maladies Métaboliques 2013;7:58-78. [DOI: 10.1016/s1957-2557(13)70494-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
545 Neff KJ, Roux CWL. Incretins: new targets for the prevention of diabetes and obesity. Clinical Lipidology 2013;8:109-121. [DOI: 10.2217/clp.12.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
546 Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications. 2013;27:401-406. [PMID: 23352496 DOI: 10.1016/j.jdiacomp.2012.12.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
547 Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:e001986. [PMID: 23355666 DOI: 10.1136/bmjopen-2012-001986] [Cited by in Crossref: 189] [Cited by in F6Publishing: 207] [Article Influence: 21.0] [Reference Citation Analysis]
548 Burmeister MA, Ayala J, Drucker DJ, Ayala JE. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose. Am J Physiol Endocrinol Metab 2013;304:E677-85. [PMID: 23341495 DOI: 10.1152/ajpendo.00446.2012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
549 Camafort-Babkowski M. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus]. Med Clin (Barc) 2013;141:167-74. [PMID: 23332622 DOI: 10.1016/j.medcli.2012.11.016] [Reference Citation Analysis]
550 Lasalle JR. Enhancing treatment success with incretin-based therapies: A comprehensive approach to the patient with diabetes. Osteopathic Family Physician 2013;5:51-57. [DOI: 10.1016/j.osfp.2012.11.002] [Reference Citation Analysis]
551 Vilsbøll T, Calanna S, Knop FK. The Role of Glucagon-like Receptor-1 Agonists in the Metabolic Syndrome. The Metabolic Syndrome 2013. [DOI: 10.1007/978-3-7091-1331-8_12] [Reference Citation Analysis]
552 Wirth A, Hauner H, Roden M, Parhofer K, May M, Engeli S, Jordan J, Schulz R, Schneider K, Grote V, Teucher B, Kaaks R. Komorbiditäten. Adipositas 2013. [DOI: 10.1007/978-3-642-22855-1_6] [Reference Citation Analysis]
553 Freeman JS. Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies. Osteopathic Family Physician 2013;5:43-50. [DOI: 10.1016/j.osfp.2012.11.001] [Reference Citation Analysis]
554 Sämann A, Müller UA. Dosage of Antihyperglycemic Drugs in Patients with Renal Insufficiency. Diabetes and Kidney Disease 2012. [DOI: 10.1002/9781118494073.ch14] [Reference Citation Analysis]
555 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 157] [Cited by in F6Publishing: 165] [Article Influence: 15.7] [Reference Citation Analysis]
556 Clardy-James S, Chepurny OG, Leech CA, Holz GG, Doyle RP. Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1. ChemMedChem 2013;8:582-6. [PMID: 23203941 DOI: 10.1002/cmdc.201200461] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
557 Elvert R, Wille A, Wandschneider J, Werner U, Glombik H, Herling AW. Energy loss via urine and faeces - a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight. Diabetes Obes Metab 2013;15:324-34. [DOI: 10.1111/dom.12030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
558 Montanya E. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012;13:1451-1467. [PMID: 22725703 DOI: 10.1517/14656566.2012.692777] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
559 Joshi PH, Kalyani RR, Blumenthal RS, Donner TW. Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data. Am J Cardiol 2012;110:32B-42B. [PMID: 23062565 DOI: 10.1016/j.amjcard.2012.08.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
560 Bays HE. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies. Am J Cardiol 2012;110:4B-12B. [PMID: 23062567 DOI: 10.1016/j.amjcard.2012.08.029] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
561 Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol. 2012;166:1586-1599. [PMID: 22519295 DOI: 10.1111/j.1476-5381.2012.01971.x] [Cited by in Crossref: 155] [Cited by in F6Publishing: 161] [Article Influence: 15.5] [Reference Citation Analysis]
562 Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2013;9:17-29. [PMID: 23094590 DOI: 10.1517/17425255.2013.731394] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
563 Sanlioglu AD, Karacay B, Balci MK, Griffith TS, Sanlioglu S. Therapeutic potential of VIP vs PACAP in diabetes. J Mol Endocrinol 2012;49:R157-67. [PMID: 22991228 DOI: 10.1530/JME-12-0156] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
564 Dong CX, Brubaker PL. Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. Nat Rev Gastroenterol Hepatol 2012;9:705-15. [PMID: 23026903 DOI: 10.1038/nrgastro.2012.185] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
565 Edwards KL, Stapleton M, Weis J, Irons BK. An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Technology & Therapeutics 2012;14:951-67. [DOI: 10.1089/dia.2012.0098.edw] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
566 Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012;34:2082-2090. [PMID: 23031623 DOI: 10.1016/j.clinthera.2012.09.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
567 Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol 2012;215:335-46. [PMID: 23019069 DOI: 10.1530/JOE-12-0368] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 9.1] [Reference Citation Analysis]
568 Shin SJ. Glucagon-like peptide-1 receptor agonists and their effects on weight reduction. J Diabetes Investig 2012;3:490-1. [PMID: 24843612 DOI: 10.1111/j.2040-1124.2012.00241.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
569 Alonso N, Julián MT, Puig-Domingo M, Vives-Pi M. Incretin hormones as immunomodulators of atherosclerosis. Front Endocrinol (Lausanne) 2012;3:112. [PMID: 22973260 DOI: 10.3389/fendo.2012.00112] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
570 Verma A. Non-diabetic use of liraglutide. Indian J Endocrinol Metab 2012;16:864-5. [PMID: 23087891 DOI: 10.4103/2230-8210.100698] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
571 Riediger T. The receptive function of hypothalamic and brainstem centres to hormonal and nutrient signals affecting energy balance. Proc Nutr Soc 2012;71:463-77. [PMID: 22931748 DOI: 10.1017/S0029665112000778] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
572 Ebdrup BH, Knop FK, Ishøy PL, Rostrup E, Fagerlund B, Lublin H, Glenthøj B. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 2012;10:92. [PMID: 22891821 DOI: 10.1186/1741-7015-10-92] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
573 Moore J, Dungan K. Glycemic variability and glycemic control in the acutely ill cardiac patient. Heart Fail Clin 2012;8:523-38. [PMID: 22999237 DOI: 10.1016/j.hfc.2012.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
574 Mathus-Vliegen EM; Obesity Management Task Force of the European Association for the Study of Obesity. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts 2012;5:460-83. [PMID: 22797374 DOI: 10.1159/000341193] [Cited by in Crossref: 163] [Cited by in F6Publishing: 170] [Article Influence: 16.3] [Reference Citation Analysis]
575 Holst JJ, Vilsbøll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab 2013;15:3-14. [PMID: 22646532 DOI: 10.1111/j.1463-1326.2012.01628.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
576 Hussain SS, Bloom SR. The regulation of food intake by the gut-brain axis: implications for obesity. Int J Obes (Lond) 2013;37:625-33. [PMID: 22710925 DOI: 10.1038/ijo.2012.93] [Cited by in Crossref: 129] [Cited by in F6Publishing: 133] [Article Influence: 12.9] [Reference Citation Analysis]
577 Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res. 2012;2012:672658. [PMID: 22675341 DOI: 10.1155/2012/672658] [Cited by in Crossref: 42] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
578 Lind M. Incretin therapy and its effect on body weight in patients with diabetes. Prim Care Diabetes. 2012;6:187-191. [PMID: 22613745 DOI: 10.1016/j.pcd.2012.04.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
579 Paul S, Best J, Klein K, Han J, Maggs D. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*. Diabetes Obes Metab 2012;14:826-34. [PMID: 22510305 DOI: 10.1111/j.1463-1326.2012.01609.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
580 Vilsbøll T, Garber AJ. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab. 2012;14 Suppl 2:41-49. [PMID: 22405268 DOI: 10.1111/j.1463-1326.2012.01579.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
581 Swithers SE, Laboy AF, Clark K, Cooper S, Davidson TL. Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats. Behav Brain Res 2012;233:1-14. [PMID: 22561130 DOI: 10.1016/j.bbr.2012.04.024] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 7.7] [Reference Citation Analysis]
582 Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11:459-471. [PMID: 22439841 DOI: 10.1517/14740338.2012.675326] [Cited by in Crossref: 126] [Cited by in F6Publishing: 134] [Article Influence: 12.6] [Reference Citation Analysis]
583 Koch L. Pharmacotherapy: GLP-1R agonists--the new weapon against obesity? Nat Rev Endocrinol 2012;8:196. [PMID: 22290361 DOI: 10.1038/nrendo.2012.13] [Reference Citation Analysis]
584 Bagger JI, Christensen M, Knop FK, Vilsbøll T. Therapy for obesity based on gastrointestinal hormones. Rev Diabet Stud 2011;8:339-47. [PMID: 22262071 DOI: 10.1900/RDS.2011.8.339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
585 [DOI: 10.1101/549857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]